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Introduction: Functional neurological symptoms are commonly reported by people 
presenting to neurology services. Symptoms are diverse, and there is little published 
evidence to inform treatment guidelines. Idiopathic drop attacks are also seen within 
neurology services, but literature about them is sparse and it is unclear whether they should 
be considered within the spectrum of functional neurological disorder.  
Aims: The aim of this thesis was to assess cognitive behavioural therapy (CBT) as an 
intervention for functional neurological disorder (FND), through a systematic review and 
meta-analysis. A second aim was to look at idiopathic drop attacks and determine whether a 
psychological understanding of these would help to inform formulation and treatment.  
Methods: A systematic review identified 28 studies of CBT for FND, nine of which were 
included in meta-analysis. In addition, a grounded theory study of idiopathic drop attacks 
was conducted through the coding and synthesis of data from interviews and diaries of 
seven individuals with FND, with the aim of identifying predisposing, precipitating and 
maintaining factors.  
Results: In the systematic review and meta-analysis, random effects models revealed a 
significant advantage of CBT over control on daily functioning, and a significant improvement 
within CBT groups over time. CBT also had a significantly positive effect on anxiety, 
depression and functional neurological symptoms, both compared to control groups, and 
within CBT groups over time. Positive effects of CBT were maintained over six months. 
In the grounded theory study, themes relating to predisposing and precipitating factors for 
drop attacks, along with thoughts, emotions and behaviour both before and after a fall, were 
identified. A cognitive behavioural model was proposed, with a traumatic first fall and life 
stressors as predisposing factors, situational triggers and increased worry as precipitating 
factors, and a maintaining cycle of thoughts, emotion and behaviour.  
Conclusions: Meta-analysis suggests that CBT may be effective for FND, and that the 
positive impact of this persists over time. However, as the evidence base is currently small, 
larger trials are required. The grounded theory study proposed a cognitive behavioural 
understanding of the onset and maintenance of idiopathic drop attacks and noted 
considerable overlap between drop attacks and non-epileptic seizures. This understanding 
could help to guide formulation, and suggests a CBT treatment approach would be worth 





Functional neurological disorder is a term used to describe symptoms which are similar to 
those seen in neurological illnesses, but which are not due to disease. They are common in 
people who go to neurology clinics. Symptoms vary, and there is little published evidence to 
inform the best course of treatment. Idiopathic drop attacks are unexplained falls to the floor, 
and are also seen within neurology services, but it is unclear whether they should be 
considered a functional neurological disorder.  
This thesis contains two papers. The aim of the first was to assess whether cognitive 
behavioural therapy (CBT; a psychological intervention which focuses on thoughts and 
behaviour) was an effective treatment for functional neurological disorder (FND), through 
reviewing the evidence. The second paper aimed to look at idiopathic drop attacks and 
determine whether a psychological understanding of these would help to inform treatment.  
In our review, we found 28 studies of CBT for FND. Results from nine high-quality studies 
were synthesised and we found that CBT improved everyday functioning, anxiety, low mood 
and functional neurological symptoms. 
For the second paper, we interviewed seven people who were experiencing drop attacks, 
and asked them to keep diaries of their falls. We found that participants had experienced a 
traumatic first fall and noted that stressful life experiences may have made the falls more 
likely to happen. People were more likely to fall in certain places, and when they were 
feeling more stressed or worried. We also found that people were more likely to cope with 
their falls by avoiding certain situations.  
Overall, the first study concluded that CBT seems to be an effective treatment for FND, but 
we need more high-quality research to determine this. The second study found that drop 
attacks are very similar to other functional neurological symptoms and that a CBT treatment 
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1.1 Abstract  
Functional neurological symptoms are common in those who present to neurology services. 
However, currently there is a sparse evidence base to inform treatment. Cognitive 
behavioural therapy (CBT) is an intervention which has been trialled with different functional 
neurological disorder (FND) presentations. We systematically reviewed CBT trials for FND to 
investigate its efficacy on daily functioning, functional neurological symptoms, and anxiety 
and depression symptoms. 
Electronic databases were systematically searched for studies investigating CBT for FND, 
and 28 studies with a total of 1010 participants were identified. Nine of these, including 
seven controlled trials, were of a methodological quality that allowed them to be combined in 
meta-analysis. 
Random effects models revealed a significant advantage of CBT over control on daily 
functioning (g=-0.44, 95% CI -0.66, -0.22, p<0.0001), and a similar effect size was seen 
within CBT groups over time (d=-0.50, CI -0.76, -0.24, p=0.0002). CBT also had a 
significantly positive effect on anxiety, depression and functional neurological symptoms, 
both compared to control and over time. At six- to twelve-month follow-up, positive effects of 
CBT had been maintained.  
CBT improved daily functioning, anxiety, depression and functional neurological symptoms 
for those with FND, and these persisted once treatment had ended. However, the 
generalisability of the estimates of effect produced here are limited due to the small number 
of small heterogeneous trials. CBT is a promising intervention for FND, and further large-
scale trials would help to determine its efficacy.  
 






Functional neurological disorder (FND) is a term which describes neurological symptoms 
which do not have an identified organic cause. DSM-5 (APA 2013) criteria for FND state that 
there must be A) One or more symptoms of altered voluntary motor or sensory function, B) 
Clinical findings that provide evidence of incompatibility between the symptom and 
recognised neurological or medical conditions, C) Symptoms or deficits that are not better 
explained by another medical or mental disorder, and D) Symptoms or deficits that cause 
clinically significant distress or impairment in social, occupational, or other important areas of 
functioning, or warrants medical evaluation. 
The prevalence of FND has been estimated at 9-30% of those presenting to neurology 
inpatient and outpatient settings (Stone et al. 2009; Lempert et al. 1990) with follow-up at 18 
months showing this initial diagnosis to be accurate in all but 0.4% of cases (Stone et al. 
2009). A large study in Scotland estimated that neurologists were diagnosing around 5000 
cases of FND per year (Stone et al. 2010a).  
Functional symptoms often persist over time, leading to increased costs to the health service 
and to the wider economy, due to reduced capacity for work (M Reuber et al. 2005). Direct 
healthcare costs alone in Scotland have been estimated to be £11.3 million, with 27% of 
patients also receiving benefits, and 50% unable to work (Stone et al. 2010a; Carson et al. 
2011). Therefore it is important that research highlights effective and acceptable treatments.  
1.2.1 Symptoms and comorbidity 
A wide variety of symptoms are included under the FND classification. These include 
paralysis, weakness, seizures, visual problems and speech problems. Other functional 
symptoms are often co-morbid with FND, such as chronic pain, headache and chronic 
fatigue (Carson et al. 2000). Although these have separate evidence bases, there are 
increasing calls for a transdiagnostic approach to functional symptoms, given the similarities 
and comorbidity between them (Chalder and Willis 2017). However, for the purposes of this 
review, the focus will be on functional neurological symptoms, as included in previous 
reviews of this population (Ludwig et al. 2018; Hopp and LaFrance 2012). 
The pattern of functional neurological symptoms can vary widely between individuals, with 
some having a single symptom and some multiple. The frequency and persistence of these 
symptoms also varies, and people may experience a single acute episode, intermittent 
symptoms or a more chronic course. This has raised questions about whether FND should 
have a single classification or whether certain presentations, such as specific clusters of 
symptoms, should be categorised separately (Stone et al. 2011; Carson and Lehn 2016).  
One of the most researched functional neurological presentations is non-epileptic seizures 
(NES), also termed ‘psychogenic seizures’, ‘dissociative seizures’, ‘functional seizures’ and 
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‘non-epileptic attack disorder’. These are ‘episodes of altered movement, sensation, or 
experience resembling epileptic seizures, but not associated with ictal electrical discharges 
in the brain’ (M Reuber 2009). Functional motor disorders (FMD), which is a term that covers 
several presentations such as weakness, gait disorders and tremor, have also been widely 
studied (Ricciardi and Edwards 2014). Less research has been conducted with other 
presentations, such as functional dizziness (Popkirov et al. 2018).  
Comorbidity between functional neurological symptoms is common. A six-year follow-up of 
73 patients with functional motor symptoms found that 44% had experienced other 
unexplained neurological symptoms (Crimlisk et al. 1998). A more recent study of functional 
weakness compared 107 patients with functional weakness to 46 patients with a 
neurological weakness. Those with functional weakness were significantly more likely to also 
experience other functional symptoms, such as non-epileptic seizures, functional tremor and 
functional dystonia (Stone et al. 2010b).  
Stone et al. (2010b) also found those with functional weakness to be significantly more likely 
to meet diagnostic criteria for other psychiatric disorders, including major depression, panic, 
generalised anxiety disorder and somatisation disorder. Seventy-five percent of the sample 
in Crimlisk and colleagues’ (1998) study also met the criteria for other psychiatric disorders.  
1.2.2 Mechanism 
There are a number of theoretical understandings of functional neurological disorders. 
Originally, functional symptoms were conceptualised as ‘hysterical conversion’ by Breuer 
and Freud (2009). The functional symptom was seen as a physical representation of 
repressed thoughts and emotions. More recently, the main model of functional symptoms 
has been the somatosensory amplification model (Barsky and Wyshak 2018), which states 
that stress related physical arousal and attention on physical symptoms leads to the 
misattribution of normal physical sensations to disease. Over time, with increased attention 
on physical symptoms, tolerance decreases and arousal increases, further exacerbating 
physical arousal symptoms (Nakao and Barsky 2007). Until recently, this has been the 
central basis of cognitive behavioural models of functional symptoms. However, it has not 
fully explained how subjective and measured stress levels can be lower in those with 
functional symptoms (Tak et al. 2011).  
The predominant current understanding of functional symptoms is a Bayesian predictive 
coding framework. A comprehensive model of functional symptoms was outlined by Van den 
Bergh and colleagues (2017), based on a review of the functional symptom literature. The 
authors suggest that functional symptoms are a set of perceptions, based on the brain’s 
interpretation of information from the body, which is guided by past experience. A cognitive 
representation of a symptom, which is preconscious in nature, is activated when certain 
triggers are present, such as physiological stress, or contextual triggers. This helps to 
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explain symptoms which occur in the absence of subjective stress, and highlights the 
importance of the individual’s interpretation of symptoms, and the context in which they 
occur.  
1.2.3 Intervention 
At present there are no official treatment guidelines, due to limited randomised controlled 
trial evidence, however various approaches have been trialled, including antidepressant use 
(Voon and Lang 2005), hypnotherapy (Moene et al. 2002), and physical therapy (Nielsen et 
al. 2013). Psychological therapies have also been investigated, including CBT, 
psychodynamic therapy, paradoxical intention therapy, mindfulness, psychoeducation, and 
eclectic interventions. A meta-analysis of these interventions for NES found them to reduce 
seizure frequency by at least 50% in 82% of participants, and psychological intervention led 
to seizure freedom in 47% of the participants in the review (Carlson and Perry 2017).  
A stepped care approach to FND was developed by a group of healthcare professionals, as 
part of an NHS Scotland healthcare improvement project (2012). The treatment approach 
outlined in the NHS Scotland report recommended that, following diagnosis, a brief, guided 
cognitive behavioural self-help programme should be delivered if required, following positive 
results from a randomised controlled trial (RCT) of such an intervention (Sharpe et al. 2011). 
However, this type of intervention may not be suitable for all patients with FND, as a degree 
of self-motivation is required for guided self-help to be an effective intervention (Coull and 
Morris 2011). 
CBT interventions have been trialled with the most common FND presentations, including 
non-epileptic seizures (LaFrance et al. 2014), functional motor disorder (Dallocchio et al. 
2016) and functional dizziness (Schmid et al. 2018). The approaches tend to have the same 
basic elements, which involve trying to interrupt current patterns of thoughts and behaviour 
through identifying negative thoughts and illness beliefs, and engaging in avoided activities 
in order to reduce any anxiety associated with them. Coping strategies such as relaxation 
exercises and distraction techniques are also developed as part of these interventions. 
CBT has been trialled with non-neurological functional symptoms, with positive results. A 
recent systematic review and meta-analysis identified 15 RCTs of CBT for ‘somatic’ or 
‘medically unexplained’ symptoms. They found CBT to significantly reduce somatic 
symptoms, anxiety symptoms and depression symptoms, and to improve physical 
functioning (Jing et al. 2019). However, this review did not include trials of common 
functional symptom presentations, such as irritable bowel syndrome (IBS) and chronic 
fatigue syndrome (CFS), and significant heterogeneity within meta-analyses was not taken 
into account. An earlier meta-analysis of 20 CBT RCTs found the intervention to be effective 
in reducing physical symptoms of IBS (d=0.73; Laird et al. 2016). An additional meta-
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analysis of 13 studies of CBT for CFS also found CBT to be effective in reducing fatigue 
compared to controls (d=0.48; Malouff et al. 2008).  
Although a previous narrative review of CBT for FND has been completed (Hopp & 
LaFrance, 2012), this is the first systematic review in this area, as far as we are aware. As 
CBT is starting to be recommended within treatment guidelines, it is important to assess the 
expanding evidence base to determine the impact of CBT on different functional neurological 
symptoms. Given ongoing debates on whether different clusters of symptoms should be 
treated as separate disorders, or different manifestations of the same underlying process 
(Carson and Lehn 2016; Stone et al. 2011), this review aimed to give an overall picture of 
the evidence base of CBT for all functional neurological symptoms. 
Our aim was to review the literature on CBT as a treatment for functional neurological 
symptoms, investigating everyday social and occupational functioning as a primary outcome, 
along with secondary outcomes of functional neurological symptoms, and symptoms of 
anxiety and depression.  
 
1.3 Methods 
The systematic review was conducted following PRISMA guidelines and a checklist is 
included in Appendix B. The protocol was registered on PROSPERO with reference number 
CRD42018093988 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=93988). 
1.3.1 Data sources 
The Cochrane Register, PsycINFO, EMBASE, MEDLINE and Web of Science were 
searched, up to November 2018, using the following phrases: 
(“functional sympto*” OR unexplained OR somati* OR conversion OR hysteri* OR 
psychogenic OR “dissociative seizure*” OR “non-epilepti*” OR nonepilepti* OR 
pseudoseizure* OR “functional motor” OR “functional weakness*” OR “functional dystonia” 
OR “postur*-perceptual” OR PPPD OR "chronic subjective dizziness" or "phobic postural 
vertigo" or "somatoform vertigo" OR (functional and (dysphagi* or dysphoni* or dysarthri*)) 
AND (“cognitive therap*” OR “cognitive behav*” OR “behav* therap*” OR “behav* treatment*” 
OR “cognitive treatment*” OR CBT OR “acceptanc* and commitment” OR "dialectical 
behav*" OR DBT OR CBASP OR "function* analyt*" OR FAP OR "relation* frame" OR 




The reference lists of all included studies were searched for other relevant studies. Papers 
which cited included studies were also checked. Corresponding authors of included studies 
and other known research groups working in the field were contacted for information 
regarding unpublished or ongoing trials. 
1.3.2 Study inclusion 
Studies had to meet the following inclusion criteria: 
1) Participants had to be adults who had been diagnosed with functional neurological 
symptoms, which would fit with diagnostic criteria for functional neurological disorder (FND). 
That is, clusters of symptoms which present as a neurological condition but for which there 
has been no identified organic basis for the symptoms experienced. This included a range of 
disorders which included functional motor disorders, non-epileptic seizures, functional 
speech disorders and functional dizziness. Although there are similarities between functional 
neurological disorders and other conditions with medically unexplained symptoms, such as 
chronic fatigue syndrome, headache and chronic pain, this review focused on conditions 
defined by clusters of functional neurological symptoms only, as included in pervious 
reviews (Hopp and LaFrance 2012; Ludwig et al. 2018). Therefore studies of more general 
‘medically unexplained symptoms’ were excluded. Studies with subgroups of patients who 
met the criteria for FND were, however, included if separate data on FND participants could 
be obtained. 
2) The studies had to be intervention studies where the treatment used was based on CBT, 
including studies of what have been termed ‘third-wave’ CBT interventions (Öst 2008).  
Interventions were assessed to identify whether they contained key components of CBT, 
specifically both cognitive and behavioural elements. Studies where participants received 
additional treatment alongside CBT were included but were highlighted as such within the 
review. 
3) Studies had to have a sample size of five or more to be included. Single-case studies 
were excluded. 
4) As the primary outcome being investigated are daily functioning (defined as general 
functioning across social, occupational and practical tasks), and secondary outcomes are 
functional neurological symptoms, anxiety and depression symptoms, studies had to report 
on a structured assessment of one or more of these areas.  
Figure 1.1 shows the flow of study inclusion. Screening was completed by the lead author 
and any studies where it was unclear whether inclusion criteria were met were discussed 





Figure 1.1 Flow diagram of study identification and inclusion 
 
1.3.3 Data extraction 
The lead author extracted data from all studies which met inclusion criteria, and data from a 
random 25% sample of these were extracted by an independent researcher to ensure 
reliability (Kappa=0.91, indicating strong agreement). Data were extracted onto standard 
forms. Extracted information included study design; intervention design, setting and duration; 











































4673 records after duplicates removed 
4673 records (titles and abstracts) 
screened against inclusion criteria 
of: 
 
1) CBT based intervention 
2) Participants with functional 
neurological symptoms 
 
4591 records excluded due to not 
meeting inclusion criteria: 
82 full-text articles 
assessed for 
eligibility 
52 articles excluded due to: 
 
1) Not exclusively functional 
neurological symptoms (n=21) 
2) Not an intervention study (n=9) or 
intervention not CBT-based (n=11) 
3) Case study only (n=9) 
4) Foreign language versions of 
included studies (n=2) 
 
28 studies (30 articles) 
included in review 
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groups and intervention/control details; outcome measures used; time points for data 
collection; and main findings.  
The Effective Public Health Practice Project (EPHPP) quality assessment tool (Thomas et al. 
2004) was used to assess the methodological quality of each study. Studies were not 
excluded from the review on the basis of methodological quality. However, only studies 
deemed to be of ‘moderate’ or ‘strong’ methodological quality were included in the meta-
analysis, in order to reduce the potential effects of bias. This is covered further in section 
1.4.4.    
1.3.4 Meta-analysis 
Where data were available, means and standard deviations were used to calculate both 
independent groups and repeated measures effect sizes in order to conduct random effects 
meta-analyses using the Cochrane Collaboration’s RevMan software (v5.3). Effect sizes as 
reported in papers were not included in meta-analysis. Consistency was measured using the 
I2 statistic and publication bias was assessed using funnel plots (Appendix I). As the number 
of studies included in each meta-analysis was fewer than ten, a formal Egger’s test (Egger et 
al. 1997) was not used (Higgins and Green 2011). 
For independent groups, Hedge’s g was calculated for each measure relating to primary or 
secondary outcomes, along with an estimate of standard error, using the following equations: 
Effect size (g) = (Mt–Mc)/SD*pooled 
Mt and Mc refer to the means of the treatment and control groups respectively and SD pooled 
is the pooled SD of both the treatment and control groups using the following equation where 
nt and nc are the sample size of the treatment and control groups and sdt and sdc are the SDs 
of each group.  
SD*pooled = sqrt([nt-1*sdt2]+[nc-1*sdc2]/nt+nc-2) 
The standard error of the effect size was calculated using the following equation where nt and 
nc are the sample sizes of the treatment and the control groups. 
SE(g) = sqrt([nt+nc]/[nt×nc])]+(g*g/[2×(nt+nc-2)]) 
For repeated measures, Cohen’s d was calculated using the equation: 
 Effect size (d) = Mpostt-Mpret/SDpret 
Mpostt is the post-treatment mean, Mpret is the pre-treatment mean, and SDpret is the pre-
treatment SD.  As r statistics were not available, standard error was calculated using the 
equation above, as described in a recent meta-analysis (Hirst et al. 2018). In this equation, nt 
and nc were replaced by the number of observations of the treatment group, giving: 
 SE(d) = sqrt([nt+nt]/[nt×nt])]+(d*d/[2×(nt+nt-2)]) 
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Different measures were included within each overall outcome effect size. However, where 
possible, sensitivity analyses were performed with a single measure, in order to determine the 
validity of this approach.  
 
1.4 Results 
1.4.1 Corpus of studies 
Table 1.1 shows summary characteristics of the 28 studies included in the review. Nine were 
described as randomised controlled trials, two were controlled trials, 11 were uncontrolled 
cohort studies (two retrospective), one was a case-control study and five were case series 
(two retrospective). A total of 1010 participants were included across the 28 studies, with a 
sample size range of 6-127, and a mean of 37 (SD=28).  
1.4.2 Target of intervention 
As shown in Table 1.1, ten studies only included people with non-epileptic seizures (NES), 
whereas one included a split sample with 63% NES and 37% other functional neurological 
symptoms, such as limb weakness (Conwill et al. 2014).  Three studies included only those 
with functional motor disorder (FMD), such as limb weakness, paralysis or stiffness. Eight 
studies included those with functional dizziness, and two included participants with functional 
dysphonia. A further six studies included participants with a range of functional neurological 
symptoms.  
1.4.3 Type of intervention 
The design, content, setting and timescale of interventions varied widely between the 
studies. CBT interventions are described in Table 1.1, with the main treatment groups 
including manualised CBT, CBT enhanced with other therapies, CBT-based 
psychoeducation, CBT-based guided self-help, and CBT-based multidisciplinary inpatient 
programs, which included input from physiotherapists, occupational therapists and 
psychiatrists, as well as psychologists. Five studies used so called “third-wave” interventions 
based on a cognitive behavioural approach; one used dialectical behaviour therapy, two 
used Acceptance and Commitment Therapy (ACT), one used Mindfulness-Based 
Psychotherapy (MBPT), and another used a combination of Mindfulness-Based Stress 
Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT).  
Eight of the interventions were delivered in a group format, whereas 14 were delivered on an 
individual outpatient basis. Six interventions were delivered in an inpatient setting, as a CBT-
based multidisciplinary approach. Two of these inpatient programs were for FMD, three for 
any FND and one for NES. Therapist contact time ranged from a total of two hours over 
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three months, as part of a guided self-help program (Sharpe et al. 2011) to an intensive 
inpatient program with a median length of 101 days (McCormack et al. 2014). Timescales 
and therapeutic contact time for each study is summarised in Table 1.1.  
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Table 1.1 Summary characteristics of included studies 




Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 




CBT and vestibular 
rehabilitation: Five 
sessions of 60-120 











treatment: DHI, VSS, 




Significant benefit of CBT 
over control on post-
treatment on DHI (Cohen's 
d=.40) and VSS (d=.44). 
Differences between 
functional and organic 
disorder not explored. 
Barrett-Naylor et al. 
(2018) 
Case series NES Guided self-help 
ACT intervention 
over six weeks, with 
weekly telephone 
support. 
None n=7 (6 completers) Baseline, post-treatment, 
1-week and 1-month 
follow-ups: DASS-21, 
QOLIE-10, CompACT, 
AAQ-II, seizure frequency 
Reliable and clinically 
significant positive change 
on compACT, DASS, QOLIE 
and seizure frequency for 
four participants.  
Baslet et al. (2015) Case series NES Individual 
mindfulness-based 
psychotherapy: 
Twelve weekly or 
biweekly sessions.  
None n=6 Baseline and post-
treatment: BDI, DASS, 
NES frequency 
No significant differences. 
Mean diff in NES frequency 
per week = 14.98 (18 at 
baseline to 2.67 at follow-up) 













n=45: 17 cases (13 







improvements in postural 
control at post-treatment 
compared to baseline.  
 
Bullock et al. (2015) Cohort NES Group DBT-skills 
training: 3 modules, 




None n=21 (19 completers) Baseline and post-
treatment: NES frequency, 
skills diary cards. Baseline 
only: demographics 
No significant differences. 
Mean diff in frequency per 
week = 9.1 (13.8 at baseline 









Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 
Chen et al. (2014) Pilot RCT NES Group CBT-based 
psychoeducation: 
One 90-minute 
session per month, 
over three months 
following diagnosis 









3 months post-diagnosis 
(post-treatment; T1) and 6 
months post-diagnosis 
(T2): WSAS, NES 
frequency, NES intensity 
Significantly better scores on 
WSAS in intervention group 
compared to control at T1 
(d=0.81, 95% CI=0.19-1.43; 
p=0.013) and T2 (d=0.69, 
95% CI=0.06-1.32; p=0.038) 
Conwill et al. (2014) Cohort NES and other 
FNS 
Group CBT-based 
therapy: 1 hour per 
week over 4-5 
weeks. 
None n=16: 10 NES, 6 
other FNS 
Baseline and post-
treatment: HADS, SF-36, 
CGI, NES frequency 
Significant improvements in 
the ‘emotional well-being’ 
(p=0.04) and ‘role limitation 
due to emotional well-being’ 
(p=0.04) sub scores of SF-
36.  
Cope et al. (2017) Cohort NES Group CBT-based 
psychoeducation: 
One 90-minute 
session per week 
over three weeks.  
None n=25 (19 completers) Baseline and post-
treatment: frequency of 
NES, intensity of NES, 
attitudes, ET7, PHQ-9, 
GAD-7, WSAS, B-IPQ, 
DES-II  
Significant improvements in 
time on ET7 (t = 2.42, 
p=0.028; d=0.38) and BIPQ 
(t=4.43, p<0.001; d=0.54) 
Dallocchio et al. (2016) Pilot RCT FMD 3 arms: Twelve-
week intervention of 
CBT (90-minute 
session once a 
week) vs CBT plus 
APA (60-minute 
session twice a 





n=37: CBT group=14 
(11 completers), CBT 
& APA group=15 (10 
completers), TAU 
control = 8 
Baseline and post-
treatment: PMDRS, HDS, 
BAI, PHQ-15 
Significant improvement on 
all outcomes over time for 
both active groups (all p < 
0.001) but not for the control 
group. Significant differences 
between CBT and TAU and 
CBT+APA and TAU at 








Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 






therapy: Six weekly 
60-minute sessions.  






treatment: GRBAS, VPQ, 
VoiSS, HADS, GHQ 
Significant benefit of CBT 
over control at post-
treatment on GHQ (p=.022). 
Both groups improved 
significantly over time on 
VoiSS, VPQ and GHQ. CBT 
group significantly improved 
over time on GRBAS and 
HADS depression.  
 








Voice therapy n=74: CBT group=37 
(33 completers), 
control group=37 (33 
completers) 
Baseline and follow-up: 
GRBAS, HADS, VPQ, 
GHQ 
CBT found to be feasible 
and acceptable. Both 
interventions had clinical 
benefits, but trial was not 
designed to assess 
between-group effects.  
Demartini et al. (2014) Cohort FND Multidisciplinary 
CBT-based 
inpatient program: 5 
days per week over 
an average of 4 
weeks. 





and 1-year follow-up: 
HoNOS, COPM, HADS, 




improvement on COPM and 
statistically significant 
improvement on CNSQ 
(p<0.001), HoNOS 
(p<0.001), HADS (p=0.004) 
and PHQ-15 (p<0.001). 









weekly 2.5 hour 
sessions.  






treatment: BSI (GSI), PSS 
Small significant positive 
effect of MBSR/MBCT on 
psychiatric symptoms 
(d=0.2, p<0.05), and large 
positive effect on perceived 
stress (d=1.41, p<0.001). 
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Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 
Edelman et al. (2012); 
Mahoney et al. (2013) 




over three weeks 
Waitlist control 
group 
n=41: 20 in initial 
treatment group (all 
completed) 
Baseline, post-treatment 
and 6-month follow-up: 
DHI, DSI, SBI, DASS-21 
 
Significant benefit of CBT 
over waitlist on DHI and SBI 
(both p<0.001), but not on 
DASS. Positive changes 
maintained at 6-month 
follow-up. 
 
Goldstein et al. (2004) Cohort NES Individual CBT over 
12 weeks: Two-
hour session in 
week one, followed 
by hour-long weekly 
or fortnightly 
session. Carer 
involvement in 3 
sessions.   
None n=20 (16 completers) Baseline, post-treatment 
and 6-months: NES 
frequency, WSAS, fear 
questionnaire, HADS, 
employment status, 
MHLC, IPQ, beliefs 
Significant improvement on 
seizure frequency, WSAS, 
and control and 
consequences subscales of 
IPQ (p≤0.01), as well as fear 
questionnaire, HADS and 
physical causes IPQ 
subscale (p<0.05). Changes 
maintained at 6-months.  
  
Goldstein et al. (2010) Pilot RCT NES Individual CBT over 
12 weeks, with one 











and 6-months: NES 
frequency, NES freedom, 
WSAS, HADS, CSRI  
Significant differences in 
seizure frequency, favouring 
CBT, at post-treatment 
(d=0.75). Both groups 
improved in some health 
service use measures and 
on the WSAS 
  
Graham et al. (2018) Case series FNS Individual ACT: one 
hour per week or 
fortnight, for up to 8 
sessions.  




improvements on WSAS 
(d=1.02), CORE-10 (d=1.70) 
and to a lesser degree on 








Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 
Holmberg et al. (2006); 
Holmberg et al. (2007) 
Controlled trial Phobic postural 
vertigo 
Individual CBT: 8-
12 sessions, each 
lasting between 45 






n=36: CBT group=18 
(16 completers), 
control group=18 (15 
completers) 
Baseline, post-treatment 
and 12-month follow-up: 
VSS, VHQ, DHI, HADS  
 
Significant benefit of CBT 
over control on VHQ and 
HADS at post-treatment 
(both p<0.01). Significant 
improvements over time in 
CBT group on DHI, VHQ and 
HADS. No significant 
treatment effects remained 
after 12 months.  
 
Jacob et al. (2018) Retrospective 
cohort 










therapy and speech 
therapy. 
 




88% of participants rated 
symptoms as improved on 
CGI at post-treatment.  
 
Kuyk et al. (2008) Cohort NES CBT-based 
inpatient program: 




family therapy and 
a variety of groups.  
None n=25 (22 completers) Baseline, post-treatment, 
6-month follow-up: NES 
frequency, SCL-90, BDI, 
STAI, UCL, SF-36, DISQ 
Significant reduction in 
seizure frequency (d=0.37, 
p=0.02), maintained at 
follow-up. Significant 
improvements also seen on 
BDI, STAI-trait, UCL-active 










Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 
LaFrance et al. (2009) Cohort NES Individual CBT: one 
hour per week, for 
12 weeks.  
None n=21 (17 completers) Baseline, and fortnightly 
thereafter: NES frequency, 
CGI, BDI, MHRSD, DTS, 
DES, BIS, FAD, SCL-90, 
GAF, OHS, LIFE-RIFT, 
WoC, QOLIE 
Significant reduction in 
seizure frequency from 17.2-
7.1 per week (d=0.44, 
p=0.001). Significant 
improvement (p<0.05) on 
BDI, DTS, BIS, FAD, SCL-
90, GAF, OHS, LIFE-RIFT, 
CGI, QOLIE  
LaFrance et al. (2014)  RCT NES Individual CBT: one 
hour per week, for 
12 weeks. 4 arms: 
CBT vs Sertraline 
vs CBT and 












Baseline, week 2, week 8, 
week 16 (post-treatment): 
NES frequency, BDI, BAI, 
BIS, DTS, DES, SEP, 
SCL-90, QOLIE, QOL-
BFS, ES, WoC, GAF, 
HDRS, CGI, LIFE-RIFT 
Significant reduction in 
seizure frequency in CBT 
group (p=0.01) and 
CBT+Sertraline group 
(p=0.008). Significantly 
greater improvement in CBT 
group, compared to TAU, on 
GAF (p=0.03), CGI (p=0.01) 
and OHF (p=0.002). 
Significantly greater 
improvement on OHF in CBT 
group compared to 
Sertraline group (p=0.01) 
and CBT+Sertraline Group 
(p=0.02).   











length of treatment 
was 101 days.    
None n=33  Baseline and post-
treatment: Mobility, ADLs, 
MRS 
Significant improvement in 
mobility (p<0.001), ADLs 
(p=0.002) and MRS 
(p<0.001) at post-treatment.  
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Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 




FND Nocebo Hypothesis 
CBT delivered in an 
inpatient setting: 2-
4 hours of therapy 
per day, over an 
average of 14 days. 
None n=13 (12 completers) Baseline, post-treatment, 
12-26 months follow-up: 
FIM 
10 patients in full remission 
following treatment. 58% had 
reliable, significant change 
on FIM. 67% full remission at 
follow-up.  




inpatient program: 5 
days per week over 
an average of 4 
weeks. 
None n=26 Baseline and post-
treatment (retrospectively 
scored), and current 
(average 7 years post-
treatment): Impact of 
symptoms, IPQ and 
WSAS 
Significant decrease in 'time 
bothered by symptoms' 
between baseline and post-
treatment (p=0.019). 58% 
thought symptoms had 
improved. Significant 
improvement on WSAS 
between baseline and follow-
up (p=0.01).   
Schmid et al. (2018) Controlled trial Functional 
dizziness 












treatment: DHI, EuroQol 
questionnaire, BSI, BCI 
Significant improvement in 
normal balance group on 
DHI (p<0.001) and BSI 
(p<0.05), but not in balance 
disorder group.  
Sharpe et al. (2011) RCT FNS Guided self-help 
(GSH): CBT self-
help manual, plus 4 
30-minute guidance 











and 6-month follow-up: 
PHQ-15, SF-12, HADS, 
WI, IPQ (and additionally 
CGI and CPS at post-
treatment only) 
Significant improvement in 
GSH group at post-
treatment, compared to TAU, 
on CGI (p=0.016), CPS 
(p=0.014), PHQ (p=0.009), 
WI (p<0.05). Significant 
benefit of GSH group over 
TAU at 6-month follow-up on 
CPS (p=0.014), SF-12 
(p=0.008) and HADS anxiety 
(p=0.028).   
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Sample size and 
attrition rate 
Outcome measures and 
timepoints a 
Main Findings 
Yu et al. (2018) RCT Functional 
dizziness 
CBT plus Sertraline 
vs Sertraline alone. 
2 one-hour CBT 
sessions per week, 
over 8 weeks. 
Sertraline 
control group 
n=91: CBT group=46, 
Sertraline group=45 
Baseline, week 2, week 4, 
week 8 (post-treatment): 
DHI, HARS, HDRS 
DHI, HDRS and HARS 
scores significantly improved 
in both groups following 
treatment (p<0.001). 
Significantly greater 
improvements seen in CBT 
group, compared to control 
group, on PHI (p<0.001), 
HDRS (p=0.005) and HARS 
(p<0.001).   
aAbbreviations:   
AAQ-II: Acceptance and Action Questionnaire 
ADLs: Activities of Daily Living 
BAI: Beck Anxiety Inventory 
BCI: Balance Control Index 
BDI: Beck Depression Inventory 
B-IPQ: Brief Illness Perceptions Questionnaire 
BIS: Barrett Impulsivity Scale 
BSI: Brief Symptom Inventory 
CEA: Confidence in Everyday Activities Questionnaire 
CGI: Clinical Global Impressions 
CNSQ: The Common Neurological Symptom Questionnaire 
CompACT: The Comprehensive Assessment of Acceptance 
and Commitment Processes 
COPM: Canadian Occupational Performance Measure 
CORE-10: Clinical Outcomes in Routine Evaluation (10 item) 
CPS: Change in Presenting Symptoms Scale 
CSRI: Client Service Receipt Inventory 
DASS: Depression Anxiety Stress Scales 
DES: Dissociative Experiences Scale 
DHI: Dizziness Handicap Inventory 
DISQ: Dissociation questionnaire 
DSI: Dizziness Symptom Inventory 
DTS: Davidson Trauma Scale 
ET7: Emotional Thermometer Scale 
ES: Expectations Scale 
FAD: Family Assessment Device 
FIM: Functional Independence Measure 
FMD: Functional Motor Disorder 
FMS: Functional mobility scale 
FND: Functional Neurological Disorder 
FNS: Functional Neurological Symptoms 
FQ: Fear Questionnaire 
GAD-7: Generalised Anxiety Disorder Assessment 
GAF: Global Assessment of Functioning 
GHQ: General Health Questionnaire 
GRBAS: Perceptual Rating of Voice Quality 
HADS: Hospital Anxiety and Depression Scale 
HARS: Hamilton Anxiety Rating Scale 
HDRS: Hamilton Depression Rating Scale 
HoNOS: Health of the Nation Outcome Scale 
IPQ: Illness Perceptions Questionnaire 
LIFE-RIFT: Longitudinal Interval Follow-Up Evaluation Range of 
Impaired Functioning 
MHLC: Multidimensional Health Locus of Control Scales 
MRS: Modified Rankin Scale 
MHRSD: Modified Hamilton Rating Scale for Depression 
NES: Non-epileptic seizures 
OHS: Oxford Handicapped Scale 
PHQ-9: Patient Health Questionnaire 
PMDRS: Psychogenic Movement Disorder Rating Scale 
PRIME-MD: Primary Care Evaluation of Mental Disorders 
PSS: Perceived Stress Scale 
QOL-BFS: Quality of Life Burden to Family Scale 
QOLIE: Quality of Life in Epilepsy-31 
SBI: Safety Behaviours Inventory 
SCL-90: Symptom checklist-90 
SEP: Side Effects Profile 
SF-12: Short form health survey (12 item) 
STAI: State Trait Inventory 
UCL: Utrecht coping list 
VHQ: Vertigo Handicap Questionnaire 
VPQ: Voice Performance Questionnaire 
VoiSS: Voice Symptoms Scale 
VSS: Vertigo Symptom Scale 
WSAS: Work and Social Adjustment Scale 
WI: Whitely Index 
WoC: Ways of Coping 
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1.4.4 Quality assessment 
Using the EPHPP quality assessment tool (Thomas et al. 2004), global ratings of quality 
were calculated based on the number of areas of bias which received a ‘weak’ rating, with 
no weak ratings indicating a strong study, one weak rating indicating a moderate study, and 
two or more indicating a weak study (Table 1.2). As well as using the tool, each study was 
assessed to determine any aspects of bias which would likely impact on the results if 
included within meta-analysis, as well as looking at any areas where the tool may not have 
accurately reflected the quality of studies in this particular population.  
One aspect of the tool which had potential to over-state bias was the blinding component. As 
most studies were using interventions with the aim of improving symptoms, and as patients 
had to be aware of this in order to consent and participate, blinding was impossible in many 
cases. Some studies also used participant-rated measures where, although some bias may 
have been present due to participants being aware of the intervention, this was not outcome 
assessor bias on the part of the research team. In these cases, the blinding component did 
not contribute to overall ratings, as noted in Table 1.2, where ratings have been put in 
parentheses. Overall, six studies were deemed to be of strong quality, six were of moderate 






























Andersson et al. (2006) weak strong strong (weak) strong weak weak 
Barrett-Naylor et al. (2018) moderate weak strong moderate weak  strong weak 
Baslet et al. (2015) moderate weak weak weak strong strong weak 
Best et al. (2015) weak moderate weak moderate weak moderate weak 
Bullock et al. (2015) strong moderate moderate (weak) weak strong moderate 
Chen et al. (2014) strong strong strong weak strong moderate moderate 
Conwill et al. (2014) moderate moderate weak weak strong weak weak 
Cope et al. (2017) strong moderate strong (weak) strong moderate strong 
Dallocchio et al. (2016) moderate strong strong moderate strong moderate strong 
Daniilidou et al. (2007) weak moderate strong moderate weak strong weak 
Deary et al. (2018) moderate strong strong weak weak strong weak 
Demartini et al. (2014) strong moderate strong weak strong weak weak 
Detert & Douglass (2014) strong moderate strong (weak) strong weak moderate 
Edelman et al. (2012) moderate strong strong (weak) moderate weak moderate 
Goldstein et al. (2004) strong moderate strong moderate strong strong strong 
Goldstein et al. (2010) moderate strong strong (weak) strong strong strong 
Graham et al. (2018) moderate weak weak (weak) strong strong weak 
Holmberg et al. (2006) moderate strong strong moderate moderate strong strong 
Jacob et al. (2018) strong moderate weak (weak) strong strong moderate 
Kuyk et al. (2008) strong moderate weak weak weak strong weak 
LaFrance et al. (2009) weak moderate strong moderate strong weak weak 
LaFrance et al. (2014)  weak strong strong moderate strong strong moderate 
McCormack et al. (2014) weak moderate strong weak weak n/a weak 
Richardson et al. (2018) weak weak weak weak moderate strong weak 
Saifee et al. (2012) strong weak strong (weak) weak n/a weak 
Schmid et al. (2018) weak strong weak moderate strong weak weak 
Sharpe et al. (2011) moderate strong strong (weak) strong strong strong 







A summary of main findings is included in Table 1.1. Most studies used outcome measures 
at baseline and post-treatment, with ten studies additionally following-up participants 
between six months and seven years post-treatment.  
Twelve of the 28 studies were rated as being of ‘moderate’ or ‘strong’ quality and were 
therefore eligible to be included in meta-analysis. However, suitable data were not available 
in three of the twelve studies. Nine studies (Chen et al. 2014; Cope et al. 2017; Dallocchio et 
al. 2016; Edelman et al. 2012; Goldstein et al. 2010; Goldstein et al. 2004; Holmberg et al. 
2006; LaFrance et al. 2014; Sharpe et al. 2011) were therefore included in meta-analyses, 
and pre-post effect sizes for the intervention group were calculated for each. Seven of the 
included studies had a control group, allowing post-intervention effect sizes to be calculated 
between treatment and control groups, excluding any measures with baseline differences 
between groups. Funnel plots did not show any evidence of publication bias. 
1.4.5.1 Daily functioning 
Twenty-one of the 28 studies used a measure of daily functioning or functional impairment. 
The Work and Social Adjustment Scale (WSAS) was the most commonly used measure of 
functioning, used in six studies.  
Between-group analysis 
Effect sizes between CBT and control groups at post-treatment were calculated for the 
seven controlled studies. Significant heterogeneity was seen (I2=55%), with two studies 
reporting larger effect sizes. Even after these were removed in a sensitivity analysis 
(reducing I2 to 0%), a significant positive effect of CBT was seen over control (g=-0.44, 95% 
CI -0.66, -0.22, p<0.0001; Figure 1.2). 
A sensitivity analysis looked at the two studies which used the WSAS as the measure of 
functioning (Chen et al. 2014; Goldstein et al. 2010), and the significant effect remained (g=-
0.68, CI -1.03, -0.33, p=0.0002). However, an additional sensitivity analysis combined the 
two studies which used the Dizziness Handicap Inventory (DHI; Edelman et al. 2012; 
Holmberg et al. 2006), and no significant overall positive effect was seen, although the effect 




Figure 1.2 Forest plot of the post-intervention effect of CBT on daily functioning, compared to control 
 
Within-group analysis 
In all nine studies included in meta-analysis, repeated measures effect sizes were calculated 
for daily functioning. However, significant heterogeneity was found (I2=66%). Three outliers 
were identified, all with larger effect sizes, and removed from the analysis. A significant 
effect of CBT over time was seen on measures of functioning (d=-0.50, CI -0.76, -0.24, 
p=0.0002; Figure 1.3), a similar sized effect as that seen in the between-groups comparison. 
A sensitivity analysis including studies which used the WSAS again showed a significant 
benefit of CBT over time (d=-0.64, CI -0.90, -0.37, p<0.00001), as did the two studies which 
used the DHI (d=-0.99, CI -1.69, -0.29, p=0.006). 
 
  
Figure 1.3 Forest plot of the pre-post effect sizes of CBT on daily functioning 
 
1.4.5.2 Functional neurological symptoms 
Functional neurological symptoms were measured as an outcome in all studies. The ten 
NES studies used frequency of attacks as a key outcome. In FMD studies, measures of 
movement disorder type (tremor, dystonia etc.), mobility, and use of aids were used. In 
functional dizziness studies, dizziness symptoms and balance measures were used. Of the 
nine studies of good methodological quality, four reported data on functional neurological 
symptoms which could be used in meta-analysis, all of which had control groups. As the 
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other five studies reported NES frequency as an outcome, these were not included due to 
the data not having normal distribution. 
Between-group analysis 
The four controlled studies had significant heterogeneity when combined (I2=92%). 
However, when an outlier with a large effect size was removed, a significant effect of CBT 
over control remained (g=-0.30, CI -0.56, -0.03, p=0.03; Figure 1.4).  
 
  
Figure 1.4 Forest plot of the post-intervention effect of CBT on functional neurological symptoms, 
compared to control 
 
Within-group analysis 
Data from four studies were used to calculate within-groups effect sizes. Significant 
heterogeneity was again present (I2=94%), and when an outlier with a larger effect size was 
removed, an overall significant positive effect of CBT over time was found (g=-0.56, CI -0.98, 
-0.13, p=0.01; Figure 1.5). 
 
  
Figure 1.5 Forest plot of the pre-post effect sizes of CBT on functional neurological symptoms 
 
1.4.5.3 Anxiety and depression symptoms 
Measures of mood and anxiety were used in 13 studies. These varied between studies, with 
the Hospital Anxiety and Depression Scale (HADS), Hamilton depression rating scale 
(HDRS), patient health questionnaire (PHQ-9) and Beck Depression Inventory (BDI) used in 




Five controlled studies reported data which could be used to calculate independent groups 
effect sizes. An additional study (LaFrance et al. 2014) collected data but effect sizes was 
not calculated for meta-analysis due to baseline differences between groups. Heterogeneity 
caused by an outlier with large positive effect sizes was seen in both depression (I2=69%) 
and anxiety (I2=51%) comparisons. After this study was excluded, a significant small positive 
effect of CBT compared to control was seen on both anxiety symptoms (g=-0.25, CI -0.50, -




Figure 1.6 Forest plot of the post-intervention effect of CBT on anxiety symptoms, compared to control 
 
  




Eight studies reported repeated-measures data on anxiety and depression symptoms. High 
but not significant heterogeneity was seen in the anxiety analysis (I2=47%), but an overall 
significantly positive effect of CBT over time was seen on anxiety symptoms (d=-0.59, CI -
0.87, -0.31, p<0.0001; Figure 1.8). When two outliers with larger effect sizes were removed 
in a sensitivity analysis, the significant effect remained (d=-0.41, CI -0.62, -0.19, p=0.0002).  
In analysis of depression symptoms, significant heterogeneity was observed due to one 
outlier with a large effect size (I2=83%). When this as removed, a significantly positive effect 
of CBT over time was seen (d=-0.37, CI -0.61, -0.13, p=0.002; Figure 1.9).  Effects remained 
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in a sensitivity analysis when only the four studies which had used the most common 
measure of anxiety and depression symptoms, the HADS, were included.  
 
  
Figure 1.8 Forest plot of the pre-post effect sizes of CBT on anxiety symptoms 
 
  
Figure 1.9 Forest plot of the pre-post effect sizes of CBT on depression symptoms 
 
1.4.5.4 Outcomes at follow-up 
Six of the studies included in meta-analysis reported six- or twelve-month follow-up data 
(Chen et al. 2014; Goldstein et al. 2010; Goldstein et al. 2004; Sharpe et al. 2011; Holmberg 
et al. 2007; Mahoney et al. 2013). Meta-analysis of three controlled studies showed that 
CBT’s significantly positive effect on functioning, compared to control was strengthened at 
six-month follow-up (g=-0.57, CI -0.84, -0.30, p<0.0001). A similar effect size was seen in 
the CBT groups in five of the six studies between baseline and follow-up, after one outlier 
was removed due to heterogeneity (d=-0.53, CI -0.84, -0.21, p=0.001).  
Only one study (Sharpe et al. 2011) reported data to calculate an independent groups effect 
size for functional neurological symptoms at six-month follow-up, which was not significant. 
However, the significantly positive effect of CBT on functional symptoms over time seen at 
post-treatment, in meta-analysis of three studies, was strengthened at follow-up (d=-0.61, CI 
-1.00, -0.21, p=0.003).  
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A meta-analysis of effect sizes between CBT and control groups at follow-up for two studies, 
with non-significant individual effect sizes, found an overall significantly positive effect of 
CBT for both anxiety symptoms (g=-0.35, CI -0.64, -0.06, p=0.02) and depression symptoms 
(g=-0.32, C I-0.61, -0.03, p=0.03), larger than immediately following treatment. The effect of 
CBT at follow-up compared to baseline was calculated for four studies, showing significantly 
positive change from baseline in both anxiety (d=-0.34, CI -0.58, -0.10, p=0.006) and 
depression symptoms (d=-0.27, CI -0.51, -0.03, p=0.03).  
 
1.5 Discussion 
This systematic review and meta-analysis is the first to explore CBT as an intervention for a 
wide range of functional neurological symptoms. Overall, based on a small number of high-
quality studies, CBT was found to significantly improve daily functioning outcomes, both 
compared to control groups, and in repeated measures comparisons. CBT also significantly 
improved functional neurological symptoms, as well as depression and anxiety symptoms. 
Our findings build on previous reviews which have suggested that psychological 
interventions are effective for non-epileptic seizures (NES; Gaynor et al. 2014; Carlson and 
Perry 2017), and that CBT is effective for reducing anxiety, depression and functional 
symptoms, and improving daily functioning, in those with non-neurological functional 
symptoms (Jing et al. 2019).  
CBT had a significantly positive effect on social and occupational functioning, with effect 
sizes in the medium range. Effects of this size were seen in both within- and between-
groups comparisons, and had slightly increased at follow-up. The effects of CBT on both 
functional neurological symptoms, and anxiety and depression symptoms were also 
statistically significant, within the small-medium range. Significantly positive change in 
anxiety, depression and functional neurological symptoms was maintained at follow-up.  
One study was an outlier in most comparisons. This was a pilot RCT with a small sample 
size investigating CBT as a treatment for functional movement disorders, compared to 
standard medical care (Dallocchio et al. 2016). The effect sizes calculated from this study 
were far larger than those seen in other studies, although overall effect sizes were still 
significant when this study was removed from meta-analyses. This was the only study 
included in meta-analysis which looked specifically at movement disorders, whereas the rest 
looked at NES (five studies), functional dizziness (two studies), and mixed functional 
symptoms (one study). This raises the question of whether CBT for movement disorders 
may have different effects than in other functional neurological disorders. However, as 
Dallocchio et al. (2016) is currently the only published RCT of CBT in this population, further 




Overall, the methodological quality of studies in this area is mixed, with only nine of the 28 
studies included in this review rated as having moderate or strong methodological quality. 
The main issues across studies were small samples and lack of outcome assessor blinding, 
leading to considerable risk of bias, and limiting the number of studies which could be 
combined in meta-analysis. Therefore, only a small number of studies were used to inform 
estimates of effect, potentially limiting the generalisability of the results.  
A limitation was the use of a structured assessment of quality which produced a global rating 
of bias. In order to ensure that areas of bias were successfully identified, and that overall 
ratings were accurate, areas of identified bias were assessed further to determine whether 
they would have an impact on the results if included in meta-analysis. Areas where the tool 
may not have accurately reflected the quality of studies in this particular population were 
also investigated further. The tool was adjusted to reflect this, although global ratings were 
still produced.  
In this review, ratings of bias were used to exclude studies from meta-analysis. This in itself 
may have biased the findings, although he steps outlined above sought to minimise this.  
Although best practice would be to have included all studies in meta-regression, the high 
number of poor quality studies would have introduced considerable error into the results and 
it was decided to exclude these for the purpose of this meta-analysis. However, all studies 
were included in the review, and a summary of results from these studies were highlighted in 
Table 1.1. 
It should also be noted that there was heterogeneity within study methods. Due to this, 
different outcome measures were combined within meta-analysis. However, where possible 
combined effect sizes were compared to specific outcome measures analysed separately, in 
order to check the validity of this method, and effect sizes were found to be comparable.  
1.5.2 Clinical implications 
CBT had a significantly positive impact on functioning, functional neurological symptoms, 
and anxiety and depression symptoms. These differences remained, and were 
strengthened, at six-month follow-up. This suggests that positive change was maintained, 
despite participants receiving no further active intervention. Given the high costs associated 
with healthcare and inability to work in those with FND (Carson et al. 2011), an effective 12-
week CBT intervention (such as were those included in this meta-analysis) with lasting 
positive effects would be an attractive treatment option. However, further research is 
required to determine whether positive effects persist for longer than six months.  
Due to the small number of studies, it was not possible to compare different symptom 
presentations or types of intervention. However, the aim of this systematic review was 
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primarily to look at the overall quality of the literature in this area, and assess whether CBT 
for FND was an intervention that warranted further exploration. There are several studies of 
CBT for NES with good methodological quality, but further trials for other functional 
symptoms are required. Overall, all studies identified reported positive outcomes from a 
CBT-based intervention, suggesting that it is a promising intervention, but further high-
quality trials are required.  
Future trials would benefit from comparing CBT to treatment as usual, with a long follow-up 
period in order to assess change over time without intervention. A six- to twelve-month 
follow-up would also help to determine the lasting effects of any positive change following 
CBT. Collecting data on social and occupational functioning, and overall emotional 
wellbeing, would help to determine the impact of CBT on quality of life and disability for 
those with FND. This is arguable more important as an outcome, for both individuals and 
services, than a reduction in functional neurological symptoms alone.  
1.5.3 Conclusions 
CBT is a promising intervention which can improve social and occupational functioning, 
functional neurological symptoms, and anxiety and depression symptoms in those with FND. 
These effects persist over time, suggesting CBT could have lasting benefits. However, 
further high quality and adequately powered trials are required to explore the effectiveness 
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Idiopathic drop attacks are falls to the floor, without warning, and without loss of 
consciousness, for which the cause is uncertain. They are poorly studied but recent 
research suggests that some drop attacks may be usefully considered as within the 
spectrum of functional neurological disorder (FND).  
The aim of this study was to develop a psychological understanding of idiopathic drop 
attacks, in order to inform formulation and treatment. Interviews and diaries were completed 
by seven individuals experiencing drop attacks, and the content of these was analysed using 
a grounded theory approach.  
Predisposing and precipitating factors for idiopathic drop attacks, along with thoughts, 
emotions and behaviour both before and after a fall, were identified through the coding and 
synthesis of data into themes. A proposed cognitive behavioural model was identified, with a 
traumatic first fall and life stressors as predisposing factors. Precipitating factors identified 
included situational triggers and increased worry. A maintaining cycle of thoughts, emotion 
and behaviour is outlined.   
Our proposed theory overlaps with cognitive behavioural models of functional symptoms, in 
particular those of non-epileptic seizures. A cognitive behavioural understanding of drop 
attacks could aid formulation in clinical practice, and suggests that cognitive behavioural 
therapy interventions for non-epileptic seizures may also be applicable in this population. 
 
Keywords: Functional neurological disorder; cognitive behavioural; idiopathic drop attacks; 
cryptogenic drop attacks; formulation  
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2.2 Introduction  
Idiopathic drop attacks have been defined as falls to the floor without warning, where there is 
no identified cause, despite comprehensive diagnostic testing to rule out other conditions 
which can cause drop attacks, such as cardiac, cerebrovascular, vestibular or seizure 
disorders [e.g. 1, 2]. They are also not caused by malfunction of the lower limbs, or changes 
in body or head posture [3]. Little research has investigated idiopathic drop attacks, with only 
two studies exploring them in detail [3, 4], although case studies have also been published 
[5, 6]. Idiopathic drop attacks have previously been referred to as ‘cryptogenic drop attacks’ 
[3] or ‘La maladie des genoux bleus’ [5]. In this paper, the term ‘drop attacks’ will be used 
synonymously with idiopathic or cryptogenic drop attacks. 
2.2.1 Prevalence 
A recent study surveyed patients with drop attacks presenting to a single neurology clinic 
over a ten-year period [4]. Eighty-three patients were identified, 89% of whom were female, 
with a mean age of 44 (range 12-78 years). In a previous study of drop attacks, Stevens and 
Matthews [3] retrospectively identified 33 patients with drop attacks who had presented to a 
neurology clinic over a twelve year period, all of whom were female. In their study, onset 
occurred on average at age 44. The age-range of onset spanned from 19 to 69, but in two 
thirds of the sample onset was between the ages of 40 and 59. Both studies were conducted 
within adult services, so it is possible that children are also affected by drop attacks, but no 
published studies are available to determine this.  
Many more women than men present with drop attacks, with women comprising 89-100% of 
the samples mentioned above. In order to investigate this prospectively in those not 
presenting specifically to neurology services, Stevens and Matthews [3] approached 100 
consecutive male surgery patients to ask if they had ever experienced ‘attacks of 
unexplained falling’, none of whom had. The authors also asked the same question of 200 
consecutive women attending a gynaecological clinic, and found that 3.5% met the criteria 
for drop attacks. This suggests that this phenomenon could account for a significant number 
of falls in women in the general population, who may not present to neurology clinics. 
However, a survey within a general setting attended by both men and women would be 
required to determine this further, as those presenting to specialist clinics may not be 
representative of the general population.  
2.2.2 Frequency  
The frequency of drop attacks varies greatly between individuals. In Hoeritzauer and 
colleagues’ [4] study, three patterns of attacks were noted: of the 57 patients for whom 
frequency was reported, 60% experienced regular attacks, which varied between ten per 
day and one per month, 30% reported single or less frequent attacks, and 10% had clusters 
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of attacks with periods of freedom from drop attacks between these. However, for 32% of 
the overall sample, the frequency was not reported. When first seen in clinic, the mean 
duration of drop attacks was 56 months (range 2-388 months). A similar frequency pattern 
was seen in the earlier study [3], with 28% having between three and 12 drop attacks per 
year, 15% having more than 12 falls per year, 45% having two falls or fewer per year, and 
12% having clusters of attacks with freedom in between. 
2.2.3 Associations 
Stevens and Matthews [3] reported that falls usually happened while walking (96%), and 
usually occurred outside of the house, although 43% also had drop attacks inside the house. 
In Hoeritzaeur et al’s [4] sample, 34% of patients could identify triggers for their drop attacks, 
such as specific places, times or situations where falls would be more likely to occur. Upon 
direct questioning, 43% of patients described a brief period prior to a drop attack where they 
would experience feelings of dissociation or depersonalisation.  
Hormonal changes were also investigated by Stevens and Matthews [3] as a potential 
association, given that the age of onset in females frequently coincides with when 
menopause could be likely to start, and due to the fact that 60% of the younger patients in 
their sample had onset of drop attacks during pregnancy. However they found no clear links 
between hormonal changes and drop attacks, although 45% of their sample did experience 
onset either during pregnancy or within three years either side of the start of the menopause.  
2.2.4 Impact 
Injuries were frequently reported as an outcome of drop attacks. In Stevens and Matthews 
[3], 93% sustained injuries to their knees, and often also to their hands, chest or face, and 
18% reported fractured or broken bones as a result of a drop attack. Hoeritzauer and 
colleagues [4] noted that 29% of their sample had documented soft tissue injuries following 
drop attacks, which is likely to be underreported. Of these, 71% had recurrent facial injuries, 
50% injured their knees and 9% also reported fractured bones. The authors of both studies 
reported that many women would become afraid to go out due to both the risk of injury and 
embarrassment, impacting on their everyday functioning.  
2.2.5 Mechanism 
The underlying mechanism for drop attacks is unclear, due to the lack of research in this 
area. Other than the two papers mentioned above, the only additional research investigating 
this group in isolation is a small number of case reports.  Butsch and Schneemann [5] 
reported the cases of two women aged 56 and 79, with recurrent drop attacks while walking, 
occurring over several years. Another case study identified a 47 year old woman’s drop 
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attacks as occurring following recollection of traumatic experiences, suggesting a 
psychological mechanism [6].  
It has been suggested that some patients with idiopathic drop attacks can be reclassified 
within the category of functional neurological disorder [FND; 4], a term which describes 
neurological symptoms where clinical signs provide positive evidence of a disorder of 
abnormal nervous system functioning rather than of neurological disease [7]. Functional 
neurological symptoms are reported to be experienced by 9-30% of those accessing 
neurology services [8, 9]. Motor ability, speech and vision can all be affected. Some clusters 
of symptoms, because they are more common, have been grouped together and researched 
more than others, such as non-epileptic seizures [NES; 10] and functional motor disorders 
[FMD; 11].  
Although there are similarities between drop attacks and NES, drop attacks are not widely 
included in studies of NES, which tend to focus on events with generalised shaking that 
superficially resemble epilepsy or events where patients fall down and lie still and 
unresponsive, superficially resembling syncope. Hubsch et al. [12] analysed clinical signs in 
145 NES and identified different subtypes of seizure, none of which covered drop attacks. 
However, Galimberti et al. [13] and Devinsky et al. [14] included patients with drop attacks 
within an NES sample, accounting for around 10% of each sample. This suggests that, at 
least in some cases, drop attacks have significant similarities to NES.  
Hoeritzauer and colleagues [4] developed a hypothesis that drop attacks represent a 
conditioned behavioural response to negative external (environmental or situational) or 
internal (anxiety symptoms or dissociation) stimuli. It is proposed that this association is 
maintained through fear of collapse and/or through the fall providing relief from negative 
stimuli. This mechanism overlaps with models of NES previously reported in the literature 
[15, 16].  
2.2.6 Therapeutic intervention 
Due to the limited literature, there are no recommended evidence-based interventions for 
drop attacks. However, Hoeritzauer and colleagues [4] report that for 12% of patients, drop 
attacks abated following an explanation of the episodes as conditioned responses, and the 
use of distraction techniques. However, they noted that 51% of their sample had reduced or 
no drop attacks when followed-up at an average of 38 months and therefore it is unclear 
how many would have experienced spontaneous resolution.  
A better understanding of drop attacks is required to guide both formulation and treatment 
approaches. Given the potential overlap between drop attacks and other functional 
symptoms, especially NES, a deeper understanding of drop attacks could help to identify 
whether psychological interventions which show some efficacy in NES, such as cognitive 
behavioural therapy [CBT; 17], may also be helpful at reducing falls in this population. A 
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CBT intervention could also focus on helping individuals to manage their condition and 
improve the ways they cope with the anxiety surrounding future falls. 
2.2.7 Aims 
The aim of our study was to explore whether a cognitive-behavioural understanding of drop 
attacks could help to guide formulation and treatment. This was investigated through the 
collection of qualitative data from interviews and diaries from individuals experiencing drop 
attacks. The data were analysed using a grounded theory approach [18] in order to better 
understand the onset of drop attacks, the impact of life stressors as well as thoughts, 
feelings and behaviour both directly before and after a drop attack. 
The primary research question was as follows: 
• What are the predisposing and precipitating factors related to drop attacks? 
Secondary research questions were: 
• What are individuals’ thoughts, emotions and behaviour immediately prior to a drop 
attack? 
• What are individuals’ thoughts, emotions and behaviour immediately following a 
drop attack? 
 
2.3 Methods  
2.3.1 Participants 
Participants were individuals who were experiencing ongoing drop attacks who were 
recruited from a neurology outpatient clinic at a regional neuroscience unit in Edinburgh, UK 
(the Department of Clinical Neurosciences, serving a population of approximately 800,000). 
Inclusion criteria were 1) Diagnosis of idiopathic drop attacks, following assessment and 
relevant investigations, 2) Aged 18+, 3) Drop attacks occurring 6+ times per year, 4) Able to 
provide informed consent. Ethical approval (Appendix D) was granted by the South 
Yorkshire Research Ethics Committee (Reference: 17/YH/0438) and the NHS Lothian 
Research and Development Office (Reference: 2017/0335). The study protocol (Appendix E) 
was registered with Clinicaltrials.gov (Reference: NCT03694769). 
 
Due to the relatively small numbers of people diagnosed with drop attacks under the care of 
the Department of Clinical Neurosciences, approximately eight new diagnoses per year [4], 
we aimed to recruit a homogenous sample of ten participants. Due to the low numbers of 
men presenting with drop attacks, an entirely female sample was therefore recruited. In 
order to maximise data, and the likelihood of approaching saturation, two methods of data 
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collection were used: interviews and written diaries. All those who had been seen at a single 
neurology clinic between 2016 and 2018 were screened for eligibility, and contacted if they 





Figure 2.1: Participant flowchart 
 
2.3.2 Design 
In this exploratory qualitative study, neurology outpatients with ongoing drop attacks 
underwent a semi-structured interview and completed written diaries for eight weeks. 
Throughout the study, participants received treatment as usual from their neurologist.  
2.3.3 Procedure 
Participants were approached by their neurologist who gave them a participant information 
sheet. If they were interested in taking part, a meeting was arranged to discuss the study 
further and obtain written informed consent. Participants met with the researcher to give 
consent and complete an hour-long interview. Following this initial interview, participants 
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were asked to record written accounts of any drop attack that occurred over the subsequent 
eight weeks during which the researcher contacted them fortnightly by telephone to discuss 
any difficulties or concerns. If participants did not experience any drop attacks during this 
period, they were asked if they would be willing to continue keeping a diary for an additional 
two to four weeks. Participants then met again with the researcher to return the diaries and 
discuss any reflections that they had about any aspect of the process.  
2.3.4 Data collection 
2.3.4.1 Semi-structured assessment interview 
The audio-recorded interview was semi-structured, with suggested questions designed to 
facilitate discussion related to the research questions. The interview schedule (see Appendix 
F) was based on a cognitively-informed clinical interview schedule, and was refined based 
on factors found previously to be relevant in this population [4], and factors commonly 
reported in discussions with a neurologist working with patients with drop attacks. The 
schedule included questions about recent drop attacks, the onset of these and relevant 
personal and social history. Participants’ experiences of drop attacks were also discussed, 
focussing on thoughts, feelings and behaviour before and after the episodes. Participants 
were also asked about the impact that drop attacks had on their everyday functioning.  
2.3.4.2 Drop attack diary  
Participants were given diaries along with an accompanying prompt sheet (Appendix G) 
which asked them to record what had happened, along with their thoughts, physical 
symptoms, feelings and behaviour, as close to the event as possible. They were encouraged 
to write detailed accounts, outlining the period before, during and after the episode, in order 
to identify any potential triggers.  
2.3.5 Analysis 
The content of the interviews and diaries was analysed using a grounded theory approach 
[18]. Following Charmaz, a constructivist stance was taken, with research questions, based 
on knowledge of the existing literature, used as a starting point to guide data collection. The 
constructivist approach also acknowledges the influence of the researcher in the collection 
and interpretation of research data. As such, critical reflexivity throughout the research 
design, data collection and interpretation process was important. A reflective journal and 
memo-writing was used throughout this process, documenting any decision making, and the 
reasons behind these, including assessing the influence of any preconceptions or prior 
knowledge. The journal was also used to record personal ‘gut feelings’ about the data, in 
order to assess this for bias, and address the influence of this on the refinement of interview 
questions and interpretation of data. 
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Using both interviews and diaries allowed information to be obtained from different 
viewpoints, enriching the data. Data from both interviews and diaries was coded in three 
stages. Initial line-by-line open coding of transcripts was completed, followed by focused 
coding which involved sorting and grouping both frequently occurring codes, and those 
which were more relevant to the research questions. The third coding stage was theoretical 
coding. This comprised looking at relationships between codes in order to identify 
hypotheses which could be integrated into a theory. An excerpt of transcript and codes is 
included in Appendix H. 
Coding was completed as data were collected, allowing refinement and changes to be made 
over the course of the data collection period. The codes that emerged from the first four 
interviews, along with memos written alongside these, were used to refine questions used in 
subsequent interviews. Focused codes and theoretical codes were refined and altered over 
time, based on information from subsequent interviews and memos.  
Several steps were taken to reduce potential bias. Memo-writing was used throughout data 
collection and analysis, in order to record reflections on the meaning in data and codes, 
explore connections between data, and outline methodological decision making. Particular 
focus was given to identifying data which was contrary to emerging themes, and which 
would not fit with a cognitive-behavioural model, or an understanding consistent with FND.  
Participants were also invited to review the codes that were identified within their interviews. 
Any discrepancies were discussed within the research team until consensus was reached.   
 
2.4 Results 
Seven participants, all women between the ages of 40 and 71, completed interviews which 
ranged from 57 to 73 minutes. Three participants also completed diaries of their drop 
attacks, writing between 250 and 1000 words. Within the eight-week diary period, one 
participant experienced one drop attack, and another had two drop attacks. The third 
participant had no drop attacks within the eight-week period and agreed to continue keeping 
a diary for a further four weeks. She subsequently experienced a cluster of five drop attacks 
over the four weeks, the first of which was a very painful fall resulting in a hospital visit. Four 
participants did not complete diaries; two did not have any drop attacks within the prolonged 
diary period, one was lost to follow-up, and another declined to take part in the diary portion 
of the research due to the perceived burden of doing so, as she was experiencing multiple 
drop attacks each day. Most participants preferred to call their drop attacks simply ‘falls’ with 
one individual also referring to them as ‘drops’. This is reflected in the content below, where 
these terms are used interchangeably.  
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2.4.1 Main themes 
The three key categories (predisposing, precipitating and maintaining factors) and nine main 
themes from the interviews and diaries are displayed in Figure 2.2. No new key themes were 
identified from the final two interviews, suggesting that theoretical saturation was 
approached [18]. Themes are described in further detail below, grouped by the categories 
given, and with relevant example quotes.   
 
 
2.4.1.1 Predisposing factors 
Table 2.1 shows example quotes illustrating the two main themes which emerged as 
predisposing factors: prior experience of falling, and life stressors. For all participants, the 
initial experience of falling was notable in one of two ways. In some, the first falls occurred 
during a particularly stressful time, and were related to medical reasons, such as low blood 
pressure, pain, Meniere’s disease or migrainous stroke. In other cases, the first falls 
themselves were the stressful event, with falls leading to significant injuries or risk to 
children. In all cases, the falls then continued, with varying courses, despite there no longer 
being a clear cause or trigger.  
Past life stressors were mentioned by all participants who experienced traumatic or stressful 
experiences in their lives prior to developing drop attacks. Most participants also reported 
current life stressors including relationship and family difficulties, chronic health difficulties, 





Pain and injury Emotional impact Worry and sense-
seeking 
Trying to cope 
Precipitating Factors 
Situational triggers High levels of stress 




caring for family members, and work stress. Only one participant reported no current life 
stressors, and she did not experience any drop attacks during the course of the study.  
 





P07: “I fell down the stairs, my neighbour was with me, she stayed with 
me in (place). She stayed along the landing from me and she was with 
me and she shouted ‘(Name)!’ I slipped and tumbled right down to the 
bottom and blood was everywhere.” 
 
P03: “I went down between the kerb and the road and I broke my ankle 
and then I had a blood clot. And I don’t know if it was the blood clot that 
I had, because I was out of action for such a long time, and I don’t know 
if it’s... and then I had to try to learn to walk again because I was 
frightened to walk because of the pain.” 
 
P06: “(The first drop was) not long after my migrainous stroke and it 
was scary. It just, just like the right side of my body wouldn’t do 
anything. And I couldn’t get up from that one. I was kind of like frozen.” 
 
Life stressors P02: “The stress of having my little boys on my own. I worried about 
having a vertigo attack when they were just going about the house. 
That was very stressful as well.” 
 
P05: “When you go through difficult situations, can that make it worse? 
So I’ve got (daughter) through leukaemia twice. My youngest…who 
was very unhappy, has gone through severe depression and self-
harming.” 
 
P07: “I had three jobs at one point just to survive…Just to survive, to 
pay the bills and survive. It’s hard on your own.” 
 




2.4.1.2 Precipitating factors 
Table 2.2 shows the main themes in the precipitating factors category: situational triggers, 
high levels of stress, and dissociation. Participants reported falling in different locations and 
situations, both outside and in the home. Falling in the home was mentioned less frequently, 
which may have been due to a lower incidence, or due to under-reporting as these falls 
tended to be accompanied by less embarrassment. For some, falls were more likely to 
happen in specific situations, particularly in places where falls had happened before. Stairs 
and steps were a particularly common place for falls to happen, with five participants 
describing falls that had happened in these circumstances. It appeared that situational 
triggers were linked to increased levels of stress, as described in the quote from participant 
two in Table 2.2.  
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Five participants identified high levels of stress as a trigger for their drop attacks. ‘Stress’ 
was the preferred word for participants to describe this feeling, although ‘anxiety’ was also 
used. For some, it was stress immediately prior to a fall which they noticed was a trigger. For 
others, they noticed falls were more likely during periods when they had a higher general 
level of stress. However, stress was not always a factor, with some falls not being linked to 
stress, as noted in the ‘Fall even when calm’ theme in Table 2.2. Two people who identified 
stress as a trigger for their falls reported that they also had falls when they were feeling 
calm. Another participant stated that they did not fall at all during particularly stressful 
periods but were more likely to have falls in the period following this. For another participant, 
they had never considered the possibility of a link between stress and their falls and were 
unsure whether this could be a factor.  
‘Detachment-type’ dissociation [19] was identified as another precipitating factor. Four 
participants reported episodes of dissociation. In some cases, these were linked to falling 
(as described in quotes in Table 2.2), with participants describing a sense of dissociation 
either prior to the fall or after they had fallen to the floor. Three participants also described 
periods of dissociation in everyday life, for example, “I would be sitting and talking to a friend 
and I would just go. And I remember talking to a friend of mine and she was going further 
and further back. She wasn’t but she was going further and further back and I had like tunnel 
vision.” (P05). 
 





P02: “If I’m in a situation like boarding an aeroplane where I’ve had a drop 
attack before then I can feel myself tensing up and thinking what if I do 
this again, which in turn probably makes it more likely that it will happen” 
 






P01: “It makes me feel anxious, because I know I’ve got all this happening 
and all this that needs to be done… but as I said I don’t know if that’s 
maybe part of why I could be falling” 
 
P02: “I know definitely that if I get anxious or stressed, that will mean I’m 
more likely to get an attack.” 
 
P03: “I do know that if I get stressed, and I get worried about something, 
I’ll have more falls.” 
 
P05: “I don’t want to be in a situation where I have to worry about (falling), 
because that would probably just make it worse. You know, people who 
have stomach problems, the more you worry about it the worse it gets.” 
 










P02: “Although, ones that happen when I’m perfectly calm, I can’t explain 
these at all.” 
 
P06: “you could say reduce your stress and then it won’t happen, well it 
still can. You can be totally stress free and standing washing your dishes 
and (fall).” 
 
P04: “What seems to happen is that, if I have a really stressful period, it 
can be not too bad, but then when the stressful period finishes, that’s me.” 
Dissociation P02: “It’s like I’m there but I’m not there. It’s somebody talking not to me 
but to somebody else. And although I can see them and I can hear them, 
it’s as if I’m away somewhere else if you see what I mean. It’s like a sort of 
dreamlike situation I’m in.” 
 
P05: “It’s hard to separate (the falls) from the dissociation, because the 
dissociation comes first.” 
 
P01: “You know, there’s nothing going on in my head, nothing happening, 
when I actually fall. Even although I’m thinking this that and the other, 




2.4.1.3 Maintaining factors 
Table 2.3 contains the themes and subthemes which fall under the maintaining factors 
category, along with supporting quotes.  
Emotional impact 
The emotional burden of drop attacks could be conceptualised in two subthemes: 
embarrassment and depression. All but one participant reported feeling embarrassed after a 
fall outside the house. Embarrassment was less, or absent, when falls happened within the 
home, and was mainly linked to falls being witnessed by other people. This theme linked to 
the ‘trying to cope’ subtheme of ‘avoidance’, where, due to embarrassment, participants 
reported going out less frequently, or trying to get out of a situation quickly after they had 
fallen. However, one participant reported no embarrassment when she fell, stating “I’ve 
really never been embarrassed or anything like that about it.” (P02). She instead preferred to 
be in places where there were more people around, which provided reassurance.  
Five participants described current low mood, often linked to their reduced levels of 
functioning due to their drop attacks, for example, “If I try to live a more normal life, and I do 
at times try, I start dropping again and it’s difficult.” (P05). Drop attacks impacted on areas of 
independence, occupation and caring for children and grandchildren: “After I had been in the 
(hospital) and stuff, my work wouldn’t take me back because they weren’t insured to have 
me in the building.” (P04). Some had experienced times where they felt that their quality of 
life was so poor that they did not feel life was worth living.  
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Worry and sense-seeking 
The first of the subthemes captured by this theme was ‘Why is this happening?’ Participants 
reported having lots of questions about why this was happening to them, compared to other 
people. They also talked about spending a lot of time trying to work out if there were any 
patterns or triggers to their falls, with the aim of trying to prevent the falls from happening. 
Four participants reported feelings of self-blame about the falls, thinking that it was their fault 
that they were happening, describing themselves as ‘stupid’ and ‘silly’.   
Four participants described worry as being a factor, both generally in daily life, and 
specifically around falling. Participants also described worrying about falls becoming worse, 
about the potential for bad injuries, and about the impact of previous injuries on their health 
in the future. This worry included ‘catastrophic’ thinking about their falls, contemplating worst 
case outcomes including death. Two participants reported that thinking about falling made it 
more likely that they would fall. In some instances, participants linked not thinking about 
falling to having fewer falls, as described in the quotes from participant one and participant 
three in Table 2.3. However, this took the form of having something else to attend to, rather 
than suppressing thoughts which participants did not find to be effective.  
Trying to cope 
Two subthemes were identified within this theme: ‘just get on’ and ‘avoidance’. Six 
participants reported that the approach they took towards their drop attacks was to ‘just get 
on’. For some this was a feeling of being resigned to having to cope with drop attacks being 
a part of their lives, and for others this was more a defiance that they were going to carry on 
regardless. However, despite trying to manage the impact of drop attacks on their lives, all 
participants still made adjustments to their lives to help them to live with the falls, either by 
avoiding certain situations or taking actions to prevent themselves from falling. Five 
participants reported avoiding certain situations, either due to fear of the response of others, 
or due to the fear of injury. This included social situations, particular locations such as 
supermarkets, and places within the home where risk was deemed to be higher, such as the 
shower. Two participants also stated that they would avoid standing or walking when they 
felt unsteady, despite this not often being a sensation that they would feel prior to a fall. 
Pain and injury 
All participants discussed sustaining injuries as a result of falls, with injuries to the face and 
knees most common. Although some participants did report significant injuries, such as 
broken bones, this was not a frequent result of a fall. One participant who could experience 
several falls a day, mentioned that she was unsure how she had not been more severely 
injured, considering she had fallen down the stairs multiple times, stating “I’ve never broke a 
bone…I don’t understand how I’ve never broke a bone” (P04).  
Participants reported that they were not usually injured after every fall, but that existing 
injuries could make falls more painful. When they were not injured, participants recovered 
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quickly, and were able to get up off the floor immediately after a fall. However, for two of the 
participants who experienced dissociation around a fall, they stated that they needed longer 
to recover, for example, “if I’m on the ground, nobody could have hauled me up because I 
think that would have made me worse. So what I say to people is if I do drop, just leave me 
and I’ll come round in my own time.” (P02).  
 
Table 2.3: Themes and supporting quotes within the maintaining factors category 
Themes Subthemes Quotes 
Emotional 
impact 
Embarrassment P01 (diary): “I felt so embarrassed and it was as quick as I 
could get up and into my car and drove away. I then felt so 
stupid and glad that there was no-one around.” 
 
P03: “The thing that I worry about is the embarrassment of 
falling. It’s got to the stage now I don’t care how bad it is 
after I’ve fallen, it’s just the fact that I’ve fallen and people 
see me.” 
 
P05: “Yeah when someone is helping me and then I’m just 
mortified and I’m embarrassed because I’ve fallen over.” 
 
P07: “You do feel embarrassed. I don’t think anybody saw 
me, that time. But you do feel embarrassed, even though 
your just by yourself.” 
 
Depression P04: “there was one stage when, not for a wee while, but 
one stage when I was like ‘what’s the point? What’s the 
point in going on anymore?’” 
 
P07: “I just can’t be bothered. Just feeling on a wee bit of a 
downer.” 
 























‘Why is this 
happening?’ 
P03: “Sometimes I keep thinking why does it happen to 
me? Why can’t somebody else have this? Why is it me 
that’s got it?” 
 
P06: “It’s also a lot of ‘why me’. Why did I get this? Was I a 
really cruel person in a previous life?” 
 
P01: “I can’t put my finger on anything that would say why 
I’m falling.” 
 
P02: “I’m trying to fathom out what I’ve been doing or what 
I’ve eaten or if I’ve overdone things, but I can’t find a 
common denominator anywhere.” 
 
P04: “But it’s just like, it’s mad. How can your body just fall 
down without any warning?” 
 
P05: “It had been years of me trying to deal with a situation 
that was a debilitating situation where I thought ‘what is 
this? Is it my fault? Am I depressed? Am I doing this to 
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myself? You know, just beating myself up as to why this 
kept happening” 
 
P07: “I still call myself stupid for doing it because I don’t 




P04: “Standing at the top of a flight of stairs scares the 
living daylights out of me. I’ll grab my husband and be like 
‘take my hand’ and he says ‘you’ll be fine’ but I says ‘you 
dinnae know that’” 
 
P03: “There was a space but I kept looking at it and 
thinking, I’m going to fall and because I thought, I did fall.” 
 
P06: “Sometimes when I do have them…I’ve been thinking 
about them, and I don’t know if that can bring them on” 
 
P01: “If I’ve got something in my head to concentrate on, I 
might not have a fall, if that’s possible.” 
 
P03: “When I’ve got (grandson), and he’s not in his 
pushchair and we’re talking and I’m holding his hand, I’m 
fine because I think I’m concentrating so much on him that 
I’m not thinking (about falling)” 
 
P07: “I try to just say ‘oh it doesn’t worry me, it doesn’t 
worry me’ but I think it really does worry me. Because I’ve 
had a few bad ones and I don’t want to go through all that 




‘Just get on’ P02: “I’m not going to stop going on holidays or doing 
anything because of it because I feel it would be taking 
control of me then. So you’ve just got to accept it and just 
carry on.” 
 
P03: “I go on holiday, I travel a lot and I travel myself as 
well. I travel all over the world. But I still fall. But I don’t 
want it to stop me going because, It’s a case of if I don’t go 
I’m actually giving in to this and I don’t want this to 
happen.” 
 
Avoidance P03: “Even when I go on holiday, when I’m on the flight, 
because it’s long flights, I won’t even get up to go to the 
toilet, because I’m terrified I’m going to fall.” 
 
P04: “Unless I’m going with somebody, I don’t feel secure 
going somewhere different. And if it’s somewhere I’ve 
never been before, I’m not going, definitely not.” 
 
P07: “If I’ve nothing to do, well what’s the point (in going 
out). And that’s a wee bit piece of mind. Because I’ve only 
fallen twice in the house, it’s always been outside.” 
 
P06: “I think that is why I tend not to go out and do things. 
Just in case. Even though now I know what (the falls) are, I 















 P01: “It felt as though my back was broken. I got a really 
excruciating pain.” 
 
P02: “The worst I’ve had is cracked ribs when I fell on my 
wooden floor in the house. Apart from that, a bump on the 
head or something.” 
 
P03 (diary): “(I) fell against the toilet bowl hit my ribs, hip, 
shoulder and neck. Also broke my front teeth and couldn’t 
breathe for a bit. Had to go to hospital.” 
 
P04: “the amount of times I’ve been in A&E with 
concussion it’s just unbelievable.” 
 
P05: “I fell on the wrist that I had broken and my knees and 
I was in so much pain I could barely walk.” 
 
P07: “I’ve got black eyes and nose and forehead swollen 
and fractured my thumb and hurt my ribs and coccyx. I 
was in agony.” 
 
P06: “Once I did crack a rib or something, and I did the 
muscle in between because I fell forward onto… I think it 
was the table. And that’s the only injury I’ve actually had, 




2.4.2 Emergent theory 
The proposed grounded theory model of the links between themes and categories is 
displayed in Figure 2.3 below. The links reported are based on those made by participants in 
interviews and diaries, however, experiences varied between participants, so not all factors 
will be relevant for all individuals or for all falls. The experiences that the participants 
reported were shaped by the research questions which were designed to elucidate potential 
predisposing and precipitating factors, along with thoughts, feelings and behaviour around 
drop attacks. The model therefore uses these as a framework to group themes, although it is 








The proposed theory is that individuals initially had an experience of a traumatic fall, which in 
most cases was due to factors such as illness or a mechanical fall. The increased stress 
around this, either due to the stress of the fall, or the stressful life situation that this 
happened within, led to the belief that falls are dangerous or to be feared. The impact of 
previous life stressors, particularly those around the period of onset, may have also 
influenced the development of drop attacks, by raising stress levels more generally, leading 
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Figure 2.3: Grounded theory model of idiopathic drop attacks 
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We propose that there is a maintenance cycle for ongoing drop attacks, whereby external 
triggers for drop attacks, such as being in a place where a fall has happened before, and/or 
internal triggers such increased worry about falling, or general heightened anxiety, lead to 
higher levels of stress. Individuals have thoughts of ‘why is this happening?’ and increasingly 
worry about falling. Stress levels and physical arousal become elevated, increasing the risk 
of a drop attack occurring. Falls frequently result in injury, pain, embarrassment and/or 
dissociation. This in turn serves to reinforce worries about falling, and leads to rumination 
about factors that may be causing the falls.   
Individuals with drop attacks try to cope with their falls by avoiding places where they feel 
they are likely to fall, or where the risk of injury from falling is higher. Some also avoid social 
situations due to the potential for embarrassment. However, the impact this has on their 
daily functioning contributes to low mood. Avoidance reinforces the belief that falls are 
dangerous and to be feared, and individuals experience increased stress when they cannot 
avoid ‘risky’ situations, further increasing the likelihood that they will have subsequent falls. 
In contrast, another approach to the falls is to ‘just get on’. However, it appeared from our 
sample that this approach was only taken in certain aspects of life, such as continuing to 
travel abroad, with all participants making some adjustments to their lives due to drop 
attacks. For some, ‘just get on’ manifested as resignation to the changes they felt they had 
to make to reduce their falls.  
 
2.5 Discussion 
2.5.1 Integration of findings to existing literature 
Overall, our model has significant overlap with a previously hypothesised understanding of 
drop attacks as a conditioned behavioural response [4]. In this previous model, a mechanical 
fall or syncope was highlighted as a precipitating factor, and internal and external triggers 
were outlined, such as high anxiety and specific situations. Maintaining factors were also 
described, such as avoidance. These factors are all present in the model presented here. 
There is considerable overlap between the model outlined in this study, and the functional 
symptoms literature, and in particular as it relates to non-epileptic seizures (NES). The fear-
avoidance model of NES, as reported in a recent paper outlining different theoretical 
understandings of NES [20] provides a CBT framework used to inform CBT interventions for 
NES [e.g. 21], and overlaps significantly with our proposed theory. This model outlines 
catastrophic thinking, fear of seizures, avoidance, and reduced functioning as important 
maintaining factors, all of which feature in our model. A more recent cognitive model of NES 




Our model also fits with the cognitive behavioural model of health anxiety, which highlights 
the maintaining factors of safety behaviours, such as avoidance, and excessive worry [23]. A 
cognitive behavioural model of somatoform disorder [24] describes a theory where an innate 
tendency towards somatic distress symptoms, along with early adverse experiences 
predispose an individual to experience increased somatic symptoms. This is further 
increased through stressful life events, and attention to symptoms. A lack of understanding 
or explanation for the symptoms increases physical anxiety and attention to symptoms, 
which become paired through classical conditioning. Avoidance of triggers for symptoms 
feeds into an operant conditioning cycle of further sensitisation. This in turn becomes a 
vicious stress maintenance cycle of increased stress and physical symptoms, avoidance and 
selective attention.  
This model of health anxiety has significant overlaps with our proposed model. However, in 
our model it is a traumatic first fall which predisposes the individual to falling rather than 
having other symptoms. Hoeritzauer et al. [4] proposed that, in individuals who are 
vulnerable to developing drop attacks through biological or biopsychosocial factors, an event 
such as a mechanical trip or fall, or an experience of syncope, can act as a triggering event. 
Worry about this then leads to a cognitive representation of drop attacks. This is in 
agreement with a recent perspective on functional symptoms was outlined by Van den 
Bergh and colleagues [25], based on a review of the functional symptom literature. The 
authors suggest that functional symptoms are a set of perceptions, based on the brain’s 
interpretation of information from the body, which is guided by past experience. A cognitive 
representation of a symptom, which is preconscious in nature, is activated when certain 
triggers are present, such as physiological stress. This fits with our model, where an 
experience of one or more falls may have led to the expectation of falling within certain 
conditions. The idea of a functional symptom developing as a result of a similar physical 
experience has been highlighted previously [26], for example, with limb weakness often 
being preceded by an injury [27] or persistent postural-perceptual dizziness (PPPD) being 
preceded by vestibular disorders [28].    
Overall, although there are factors within our model that would be present in those with 
recurrent mechanical falls, such as avoidance and embarrassment, there are also elements 
which highlight this as a potential form of FND. Namely, that stress and worry can be 
precursors to a fall, along with dissociation. Dissociation was a significant theme in our study 
and is also central to NES. Goldstein and Mellers [29] proposed a model of NES where 
seizures are described as a dissociative response to arousal, despite a lack of reported 
general anxiety, with avoidance as a key maintaining factor. This fits within our model and 
may also help to explain drop attacks which occur without a subjective feeling of stress.  
Therefore, our theory appears to fit best with a cognitive behavioural model of functional 
symptoms, with particular overlap with models of NES. This model may be best understood 
as a ‘meta-model’, as are other cognitive behavioural models of functional symptoms [24], 
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whereby individuals’ experiences differ but the model serves as a framework to make sense 
of their experiences, rather than showing prescriptive pathways.  
2.5.2 Methodological limitations 
A limitation was that participants were recruited from the clinic of a single neurologist with a 
special interest in functional neurological disorders, and who often explained drop attacks to 
patients within a conditioned behavioural framework. To assess possible bias from this, 
participants were asked what their neurologist’s understanding of their drop attacks was. It 
transpired that participants had not taken on this understanding, and instead the 
predominant view was that nobody knows why the falls are happening. However, this 
potential bias was also held in mind throughout analysis, and particular care was taken to 
look for codes and themes which were contrary to this.  
Due to the fact that data about drop attacks were collected from individuals who had been 
experiencing falls for a long time, more information was available to inform the maintenance 
of drop attacks rather than their onset. Future research with individuals who have had a 
more recent onset would help to develop this part of the model further. However, this is 
limited by the delay individuals usually experience between first onset and diagnosis, due to 
referral pathways and the need for diagnostic tests.  
Our study included a small sample, although it was homogenous, and theoretical saturation 
was approached, with no new key themes identified in the final two interviews. Recruitment 
was carried out in a systematic way but it is possible that those who were willing to engage 
with a psychologist may not be representative of most of those who have drop attacks, given 
that those with functional neurological symptoms are often reluctant to engage in 
psychological treatment [30]. However, only one participant who was approached stated that 
she was not willing to take part due to previous negative experience of psychology services.    
The demographics of our sample fit with those in previous studies of drop attacks [3, 4], but 
there are others who experience falls who were not captured in this sample, such as men 
and younger women. Although onset was at a younger age for many participants, their 
beliefs, contributing factors and life circumstances may have changed significantly and will 
not be captured in this data. A larger sample would be required to explore this further.  
2.5.3 Clinical implications and future research 
The themes and links highlighted in this research may help to aid formulation and treatment 
planning in clinical settings. If a cognitive-behavioural model fits with an individual’s 
symptoms, it may be that a CBT approach could be beneficial for them. Given the significant 
overlap between NES and drop attacks, understanding and formulating drop attacks as a 
form of NES may be beneficial in terms of understanding and treating them. As the 
unpredictability of drop attacks appeared to increase worry about falling, giving patients a 
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clear formulation of their falls could help to begin to reduce their worry and anxiety about 
them, and encourage them to make behavioural changes to reduce their avoidance and 
improve their daily functioning. Participants also reported feeling very alone with their falls, 
and some mentioned that they would appreciate contact with others who had similar 
experiences.  
Randomised controlled trials of CBT for NES have shown positive results, reducing seizure 
frequency and improving daily functioning [17, 31], and a large multicentre randomised 
controlled trial is currently ongoing [32]. These interventions provide psychoeducation about 
NES and use CBT techniques to help patients to identify triggers, address thoughts and 
illness beliefs, develop coping strategies for life stressors, engage in avoided activities, learn 
seizure control techniques and address low self-esteem, low mood, or anxiety. These 
techniques would all be relevant within our proposed theory of drop attacks.  
It would be beneficial for future research to further explore the spontaneous resolution that 
some individuals experience and identify factors which potentially contribute to this. This 
could help to determine optimum treatment approaches. Future research should also focus 
on identifying individuals who were not included demographically in this sample, such as 
men and younger women, to see whether their experiences also fit with our model. 
 
2.5.4 Conclusion 
Idiopathic drop attacks may be best understood in the category of functional neurological 
symptoms. Our theory shows significant overlap with cognitive behavioural models of NES 
and other functional symptoms, and suggests that formulation and treatment within this 
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the information matches. More information.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in
the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent
publication' for more information), that it is not under consideration for publication elsewhere, that
its publication is approved by all authors and tacitly or explicitly by the responsible authorities where
the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in
English or in any other language, including electronically without the written consent of the copyright-
holder. To verify originality, your article may be checked by the originality detection service Crossref
Similarity Check.
Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy.
Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple,
redundant or concurrent publication' for more information).
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences,
and promotes equal opportunities. Articles should make no assumptions about the beliefs or
commitments of any reader, should contain nothing which might imply that one individual is superior
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to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive
language throughout. Authors should ensure that writing is free from bias, for instance by using 'he
or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping
(e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their
manuscript and provide the definitive list of authors at the time of the original submission. Any
addition, deletion or rearrangement of author names in the authorship list should be made only
before the manuscript has been accepted and only if approved by the journal Editor. To request such
a change, the Editor must receive the following from the corresponding author: (a) the reason
for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they
agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of
authors after the manuscript has been accepted. While the Editor considers the request, publication
of the manuscript will be suspended. If the manuscript has already been published in an online issue,
any requests approved by the Editor will result in a corrigendum.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see
more information on this). An e-mail will be sent to the corresponding author confirming receipt of
the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version
of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations. If
excerpts from other copyrighted works are included, the author(s) must obtain written permission
from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for
use by authors in these cases.
For gold open access articles: Upon acceptance of an article, authors will be asked to complete an
'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access
articles is determined by the author's choice of user license.
Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More
information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement then this should
be stated.
Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply
with their funder's open access policies. Some funding bodies will reimburse the author for the gold
open access publication fee. Details of existing agreements are available online.
After acceptance, open access papers will be published under a noncommercial license. For authors
requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.
Open access
This journal offers authors a choice in publishing their research:
Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through
our universal access programs.
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• No open access publication fee payable by authors.
• The Author is entitled to post the accepted manuscript in their institution's repository and make this
public after an embargo period (known as green Open Access). The published journal article cannot be
shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-
reviewed research in journal publications. The embargo period for this journal can be found below.
Gold open access
• Articles are freely available to both subscribers and the wider public with permitted reuse.
• A gold open access publication fee is payable by authors or on their behalf, e.g. by their research
funder or institution.
Regardless of how you choose to publish your article, the journal will apply the same peer review
criteria and acceptance standards.
For gold open access articles, permitted third party (re)use is defined by the following Creative
Commons user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective
work (such as an anthology), as long as they credit the author(s) and provided they do not alter or
modify the article.
The gold open access publication fee for this journal is USD 2850, excluding taxes. Learn more about
Elsevier's pricing policy: https://www.elsevier.com/openaccesspricing.
Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of green open
access options available. We recommend authors see our open access page for further information.
Authors can also self-archive their manuscripts immediately and enable public access from their
institution's repository after an embargo period. This is the version that has been accepted for
publication and which typically includes author-incorporated changes suggested during submission,
peer review and in editor-author communications. Embargo period: For subscription articles, an
appropriate amount of time is needed for journals to deliver value to subscribing customers before
an article becomes freely available to the public. This is the embargo period and it begins from the
date the article is formally published online in its final and fully citable form. Find out more.
This journal has an embargo period of 12 months.
Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career
researchers throughout their research journey. The "Learn" environment at Researcher Academy
offers several interactive modules, webinars, downloadable guides and resources to guide you through
the process of writing for research and going through peer review. Feel free to use these free resources
to improve your submission and navigate the publication process with ease.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of
these). Authors who feel their English language manuscript may require editing to eliminate possible
grammatical or spelling errors and to conform to correct scientific English may wish to use the English
Language Editing service available from Elsevier's WebShop.
Submission
Our online submission system guides you stepwise through the process of entering your article
details and uploading your files. The system converts your article files to a single PDF file used in
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for
final publication. All correspondence, including notification of the Editor's decision and requests for
revision, is sent by e-mail.
Submit your article
Please submit your article via http://ees.elsevier.com/eb.
PREPARATION
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Peer review
This journal operates a single blind review process. All contributions will be initially assessed by the
editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of
one independent expert reviewer to assess the scientific quality of the paper. The Editor is responsible
for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More
information on types of peer review.
Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text
should be in single-column format. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. In particular, do not use the word
processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts,
superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each
individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
The electronic text should be prepared in a way very similar to that of conventional manuscripts (see
also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics
will be required whether or not you embed your figures in the text. See also the section on Electronic
artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods
that are already published should be summarized, and indicated by a reference. If quoting directly
from a previously published method, use quotation marks and also cite the source. Any modifications
to existing methods should also be described.
Results
Results should be clear and concise.
Discussion
The Discussion section should explore the significance of the results of the work, not repeat them.
Results and Discussion should be separate and may be organized into subheadings. Avoid extensive
citations and discussion of published literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s)
of each author and check that all names are accurately spelled. You can add your name between
parentheses in your own script behind the English transliteration. Present the authors' affiliation
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address.
Provide the full postal address of each affiliation, including the country name and, if available, the
e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. This responsibility includes answering any future queries about
Methodology and Materials. Ensure that the e-mail address is given and that contact details
are kept up to date by the corresponding author.
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• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Please note that proprietary names for drugs should not be used in the article title.
Highlights
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights
are optional and should be submitted in a separate editable file in the online submission system.
Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters,
including spaces, per bullet point). You can view example Highlights on our information site.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images
and in accordance with all technical requirements.
Highlights are mandatory for Original Reports and Reviews only. They are optional but encouraged
for all other article types.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes
of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When
funding is from a block grant or other resources available to a university, college, or other research
institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
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This research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors.
Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If
other units are mentioned, please give their equivalent in SI.
Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in
line with normal text where possible and use the solidus (/) instead of a horizontal line for small
fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often
more conveniently denoted by exp. Number consecutively any equations that have to be displayed
separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate
the position of footnotes in the text and list the footnotes themselves separately at the end of the




• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or
use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
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Color figures for exclusive use as cover illustration may be submitted by authors who are also
submitting a manuscript for consideration. These figures should relate to the manuscript being
submitted as well as the larger scope and focus of Epilepsy & Behavior.
Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but
concerned about the quality of the images accompanying their article. Elsevier's expert illustrators
can produce scientific, technical and medical-style images, as well as a full range of charts, tables
and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve
them to a professional standard. Please visit the website to find out more.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference
management software products. These include all products that support Citation Style Language
styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select
the appropriate journal template when preparing their article, after which citations and bibliographies
will be automatically formatted in the journal's style. If no template is yet available for this journal,
please follow the format of the sample references and citations as shown in this Guide. If you use
reference management software, please ensure that you remove all field codes before submitting
the electronic manuscript. More information on how to remove field codes from different reference
management software.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/epilepsy-and-behavior
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When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun
2010;163:51–9. https://doi.org/10.1016/j.Sc.2010.00372.
Reference to a journal publication with an article number:
[2] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. Heliyon.
2018;19:e00205. https://doi.org/10.1016/j.heliyon.2018.e00205
Reference to a book:
[3] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.
Reference to a chapter in an edited book:
[4] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.
Reference to a website:
[5] Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 13 March 2003].
Reference to a dataset:
[dataset] [6] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt
disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/
xwj98nb39r.1.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6
should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for
Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples
of Formatted References).
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Video
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. . In order to ensure that your video or animation material is directly
usable, please provide the file in one of our recommended file formats with a preferred maximum
size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in
the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply
'stills' with your files: you can choose any frame from the video or animation or make a separate
image. These will be used instead of standard icons and will personalize the link to your video data. For
more detailed instructions please visit our video instruction pages. Note: since video and animation
cannot be embedded in the print version of the journal, please provide text for both the electronic
and the print version for the portions of the article that refer to this content.
Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage
more closely with your research. Follow the instructions here to find out about available data
visualization options and how to include them with your article.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
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supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
Research data
This journal encourages and enables you to share data that supports your research publication
where appropriate, and enables you to interlink the data with your published articles. Research data
refers to the results of observations or experimentation that validate research findings. To facilitate
reproducibility and data reuse, this journal also encourages you to share your software, code, models,
algorithms, protocols, methods and other useful materials related to the project.
Below are a number of ways in which you can associate data with your article or make a statement
about the availability of your data when submitting your manuscript. If you are sharing data in one of
these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to
the "References" section for more information about data citation. For more information on depositing,
sharing and using research data and other relevant research materials, visit the research data page.
Data linking
If you have made your research data available in a data repository, you can link your article directly to
the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with
relevant repositories, giving readers access to underlying data that gives them a better understanding
of the research described.
There are different ways to link your datasets to your article. When available, you can directly link
your dataset to your article by providing the relevant information in the submission system. For more
information, visit the database linking page.
For supported data repositories a repository banner will automatically appear next to your published
article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053;
PDB: 1XFN).
Mendeley Data
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and
processed data, video, code, software, algorithms, protocols, and methods) associated with your
manuscript in a free-to-use, open access repository. During the submission process, after uploading
your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley
Data. The datasets will be listed and directly accessible to readers next to your published article online.
For more information, visit the Mendeley Data for journals page.
Data statement
To foster transparency, we encourage you to state the availability of your data in your submission.
This may be a requirement of your funding body or institution. If your data is unavailable to access
or unsuitable to post, you will have the opportunity to indicate why during the submission process,
for example by stating that the research data is confidential. The statement will appear with your
published article on ScienceDirect. For more information, visit the Data Statement page.
AFTER ACCEPTANCE
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
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We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free
access to the final published version of the article on ScienceDirect. The Share Link can be used for
sharing the article via any communication channel, including email and social media. For an extra
charge, paper offprints can be ordered via the offprint order form which is sent once the article is
accepted for publication. Both corresponding and co-authors may order offprints at any time via
Elsevier's Webshop. Corresponding authors who have published their article gold open access do
not receive a Share Link as their final published version of the article is available open access on
ScienceDirect and can be shared through the article DOI link.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from
Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will
be published.
© Copyright 2018 Elsevier | https://www.elsevier.com
Appendix D: Ethical approval letters 
 




Yorkshire & The Humber - South Yorkshire Research Ethics Committee 
 
Room 001 
Jarrow Business Centre 
Rolling Mill Road 
Jarrow 
Tyne & Wear 
NE32 3DT 
 




14 December 2017 
 
Dr Emily Revell 
Clinical Psychology, School of Health in Social Science 
University of Edinburgh, Medical School (Doorway 6) 




Dear Dr Revell  
 
Study title: Developing a psychological understanding of idiopathic 
drop attacks 
REC reference: 17/YH/0438 
Protocol number: CAHSS1710/03 
IRAS project ID: 233998 
 
The Proportionate Review Sub-committee of the Yorkshire & The Humber - South Yorkshire 
Research Ethics Committee reviewed the above application on 14 December 2017. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date of 
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website which was searchable by any of the common internet search engines. Therefore A50 of 
the IRAS form needed to be amended. 
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1 Introduction 
Idiopathic drop attacks (IDAs) have been defined as falls to the floor without 
warning, where there is no identified organic cause, despite diagnostic testing. They 
are not caused by malfunction of the lower limbs, changes in body or head posture, 
or vertigo. There is also no loss of consciousness and recovery is rapid. Despite this 
fast recovery, people can experience significant injuries and fear about further falls, 
impacting on their everyday functioning.  
This phenomenon was highlighted by Stevens and Matthews (1973) who recruited 
33 patients from a neurology clinic and seven from a gynaecological clinic. They 
also approached 100 men who were admitted for routine surgery but found that 
none of these had experienced drop attacks. Therefore their sample was entirely 
female, with onset occurring on average at age 44. Although the age-range of onset 
spanned from 19 to 69, in two thirds of the sample onset was between the ages of 
40 and 59.  
The authors ruled out obesity, vascular disease, epilepsy, vestibular disease, limb 
weakness and hypothyroidism as contributing to IDAs. They investigated hormonal 
changes, given that the age of onset coincided with when menopause could be 
likely to start and due to the fact that 60% of the younger patients had onset of IDAs 
during pregnancy. Despite this, the authors found no clear links between hormonal 
changes and IDAs, although 45% did experience onset either during pregnancy or 
within 3 years either side of the start of the menopause.  
The frequency of IDAs varied greatly between individuals but ranged from two to 
more than 12 falls per year, usually while walking. This was more likely to happen 
when out of the house but over half of the sample also reported falling at home. 
These falls would lead to injury to the knees and often also to the hands, chest and 
face. 18% reported having fractured or broken bones as a result of an IDA. Given 
the age of onset, the increased likelihood of osteoporosis would also increase the 
risk of more severe injury as a result of IDAs. The authors also reported that many 
women would become afraid to go out due to both the risk of injury and 
embarrassment.  
Although it is undocumented, the prevalence of IDAs could be relatively high. As 
part of their recruitment process, the Stevens and Matthews (1973) asked 200 
consecutive patients at a gynaecology clinic whether they had experienced falls and 
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found that 3.5% met the criteria for IDA. This suggests that this phenomenon could 
account for a significant number of falls in women in the general population. 
There are similarities between IDAs and psychogenic non-epileptic seizures 
(PNES). However, IDAs are not included widely included in studies of PNES, which 
tend to focus on ‘convulsive’ seizures. Hubsch et al. (2011) analysed clinical signs 
in 145 PNES and identified different subtypes of seizure, none of which covered 
IDAs. However, Galimberti et al (2003) and Devinsky et al (1996) included patients 
with IDA within a PNES sample, accounting for around 10% of each sample. There 
has been no published research investigating this group in isolation since Stevens 
and Matthew’s (1973) study other than a small number of case reports (Butsch & 
Schneemann, 2014), one of which identified a woman’s IDAs as occurring following 
recollection of traumatic experiences, suggesting a psychological mechanism 
(Wilner at el., 2010).  
A paper which is currently being prepared for submission by Dr Hoeritzauer, Dr 
Carson & Dr Stone at the Department of Clinical Neurosciences, Edinburgh, 
identified 83 patients who had attended a neurology clinic over nine years who 
described experiencing these attacks. This led the authors to develop a hypothesis 
that IDAs are a conditioned behavioural response to negative external 
(environmental or situational) or internal (anxiety symptoms or dissociation) stimuli. 
This association is maintained through fear of collapse and/or through the fall 
providing relief from the negative stimuli. This type of mechanism has been 
highlighted previously in functional neurological disorders, where limbic regions 
were found to have a greater influence on motor preparatory regions when in a state 
of arousal (Voonet al., 2011). 
As the underlying mechanism of IDAs is unknown, there is currently no treatment 
available. However, Hoeritzauer and colleagues report that a small number of 
patients saw their IDAs resolve following an explanation of the episodes as 
conditioned responses and the use of distraction techniques. A psychological 
understanding of the problem could help to identify a potential psychological 
intervention. Such interventions have been found to be effective for PNES, 
particularly cognitive behavioural therapy (Goldstein et al., 2010). This type of 
intervention could focus on helping individuals to manage their condition and 
improve the ways they cope with the anxiety surrounding future falls, rather than 
necessarily seek to resolve the IDAs. 
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This research aims to explore a psychological understanding of drop attacks. This 
will be investigated through the collection of qualitative data from interviews and 
recorded diaries from individuals experiencing IDAs. The data will be analysed 
using a grounded theory approach in order to better understand the onset of drop 
attacks, the impact of life stressors as well as thoughts, feelings and behaviour both 
directly before and after a IDA. 
2 Aims 
The main aim of this research is to develop a psychological understanding of 
idiopathic drop attacks. The primary research question is as follows: 
• What are the predisposing and precipitating factors related to the onset of 
IDAs? 
Secondary research questions are: 
• What are individuals’ thoughts, emotions and behaviour immediately prior to 
an IDA? 
• What are individuals’ thoughts, emotions and behaviour immediately 
following an IDA? 
3 Methods 
3.1 Participants 
Participants will be ten individuals who are experiencing ongoing IDAs. Inclusion 
criteria are 1) Aged 18+, 2) IDAs occurring 6+ times per year, 3) Able to provide 
informed consent. Exclusion criteria are 1) Diagnosis which would provide an 
alternative explanation for drop attacks. 
3.2 Design 
In this exploratory qualitative study, neurology outpatients with ongoing IDAs will 
undergo psychological assessment and complete written diaries for eight weeks. 
Throughout the study, participants will receive treatment as usual from a 
neurologist.  
3.3 Procedure 
Participants will be recruited from a neurology outpatient clinic at the Department of 
Clinical Neurosciences in Edinburgh where they will be approached by their 
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consultant who will give them a participant information sheet. If they are interested 
in taking part, a meeting will be set up with the researcher to discuss the study 
further and obtain written informed consent. 
Participants will then meet with the researcher to complete an initial psychological 
interview which will be audio recorded. This interview will follow a standard initial 
psychological interview structure and will aim to gain information about the person’s 
experiences of IDAs, along with relevant personal and social history. The interview 
schedule is included in appendix 1.  
Following this initial interview, participants will be asked to record written accounts 
of any IDA, detailing their thoughts, physical arousal, feelings and behaviour, as 
close to the event as possible. They will be encouraged to record detailed accounts, 
outlining the period before, during and after the episode, in order to identify any 
potential triggers. They will be shown an example of a completed diary in order to 
help them to understand what they need to do. Participants will be asked to record 
such events over a period of eight weeks during which the researcher will contact 
them fortnightly to discuss any difficulties or concerns. If participants do not 
experience any drop attacks during this period, they will be asked if they want to 
continue recording diaries for an additional two to four weeks. 
Following completion of this period, participants will meet again with the researcher 
to return the diaries and discuss any patterns noticed in the interview and diaries. 
The researcher will also answer any further questions that the participant has about 
the study.  
3.4 Measures 
3.4.1 Semi-structured assessment interview 
This audio-recorded 60-minute interview will follow the format of an initial 
psychological assessment and will allow discussion of presenting problems and 
relevant personal and social history. This will allow potential predisposing and 
precipitating factors to be identified. Participants’ experiences of IDAs will also be 
discussed, focussing on thoughts, feelings and behaviour before and after the 
episodes. The participants will also be asked about the impact that these have had 
on their everyday functioning.  
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3.4.2 IDA record  
Participants will be asked to write an account of any IDAs. They will be shown an 
example diary and will also be given a prompt sheet, asking them to recall any 
triggers, feelings, physical arousal, thoughts and behaviour both directly before and 
after the episode. This diary will be completed by participants as close to the 
episode as possible. 
4 Sample size 
In order to address all three of the research questions, a qualitative approach will be 
used. An overall sample size of ten should be sufficient to allow themes to be 
identified. A purposive sampling method will be used to recruit younger participants 
as well as those who are in the average age range for onset. This will allow any 
differences between these two groups to be explored further. As the inclusion 
criteria specifies 6+ IDAs per year, this will ensure a fairly homogenous sample in 
terms of frequency of IDAs.  
There is a sample of approximately 40 patients who had ongoing drop attacks in 
July 2016 which can be recruited from. One to two new referrals per month are 
currently being made to Dr Jon Stone, and these patients can also be approached. 
This is a relatively small pool and there can be some unwillingness to engage with a 
psychological approach within the functional neurological population. However, as 
this study is aiming to help better understand participants’ experiences, rather than 
investigating psychological treatment, this may enhance engagement. Attrition is 
also a factor but, as the primary research question relies on information from the 
initial interview, the risk of this is reduced. Therefore, recruiting a purposive sample 
of ten participants should be achievable. 
5 Analysis 
The content of the psychological interviews and diaries will be analysed using a 
grounded theory approach in order to meet all of the study objectives.  Using both 
initial interviews and recorded accounts will allow information to be obtained from 
different viewpoints, enriching the data. This data will be coded by initially naming 
each segment of data and then synthesising the most common codes to identify 
themes. From these, theories can be developed regarding predisposing and 
precipitating factors. Themes regarding thoughts, emotions and behaviour can also 
be explored.  
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Participants will be invited to review the themes that were identified within their 
interviews. This will take the form of the researcher presenting the themes and 
recording whether participants agree with them or not. This will help the researcher 
to ensure that the analysis is valid. 
6 Timetable 
• Recruitment start – January 2018 
• Data collection start – January 2018 
• Data collection finish – December 2018 
• Analysis – January 2019 
• Article ready for submission – April 2019 
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Version 1 (28/09/2017) 
INTERVIEW GUIDE 
Developing a psychological understanding of 
unexplained drop attacks 
 
Name of Researcher: Emily Revell (Trainee Clinical Psychologist) 
 
This guide follows a standard initial psychological assessment structure. It includes 
general areas of discussion as well as examples of questions that will be asked in 
each area. The interview will cover these general areas but additional and 
alternative areas may be explored and different questions asked in order to gain rich 
data.  
Throughout the guide, suggested statements by the interviewer are in italics. 
 
Introduction 
Thank you for agreeing to be interviewed as part of this research project. As you are 
aware, this interview is being recorded.  
Anything you tell me will be kept confidential. The only time I may need to break this 
confidentiality is if I believe there is a risk of harm to either yourself or others. If this 
comes up, we can discuss it and make a plan together. 
I am going to ask you some questions about your drop attacks and other aspects of 
your life to try to help me understand what it is like for you. If at any point you feel 
that you do not want to continue, or if you don’t want to answer any questions, 
please let me know. 




 Description of attacks  
 Can you tell me a bit about your drop attacks? 
 
 Why was help sought?  
 Why and when did you start seeing Dr Stone? 
 
 Recent examples of drop attacks (with as much detail as possible) 
 Can you tell me about the last drop attack you had? 
 
 Frequency, duration, severity, distress 
 How often do you have them? 
 How long do they last? 
 What do they feel like? (0-100 rating for intensity of emotion) 
 How do you feel before/after? (0-100 rating for intensity of emotion) 
 Do you have injuries as a result? 
 
 How the problem impacts on functioning/interferes with daily life 
 Do the drop attacks make it hard to do other things? 
 If you didn’t have drop attacks, what would your life look like? 
 On a scale of 1-100, how much does it interfere with your life? 
 
 Situational triggers 
 Do the attacks happen in particular places/times/with certain people? 
 
 Modulators 
 Is there anything that makes them not as bad/frequent? 
 Is there anything that makes them worse? 
  
 Avoidance 
 Is there anything that you don’t do anymore because of the drop 
attacks? 
 Have they changed the way you do things? 
 
 Coping strategies – adaptive or maladaptive  
 What helps you to cope? 
 On a scale of 1-100, how well do you feel you are coping with them? 
 
 Beliefs about the problem 
 Why do you think the drop attacks happen? 
 What do your close family members/friends think about the drop 
attacks? 
 What is Dr Stone’s explanation? Does this sound right to you? 
 How much control do you think you have over the drop attacks? (0-
100 rating) 
 How much control do you think Dr Stone / your medical team has 
over the drop attacks? (0-100 rating) 
 
History and Onset of Problems 
 
 When did you first start having drop attacks? 




 What was going on when they first started? 
 Had there been any changes in your life? 
 Was anything stressful happening in your life at the time? 
 Why do you think they started? Why then? 
 
 Time course 
 Have the drop attacks changed over time? 
 Have they got better/worse? 
 
 Previous episodes 
 Have you had drop attacks or something similar another time in your 
life? 
 Was there anything that helped then?  
 Did you see anyone about them then? 
 
 Family history 
 Is there a family history of drop attacks/related disorders/medical 




 General enquiries about distress, concerns and well-being– stability/changes 
 
 Co-morbidity 
 How do you generally feel in yourself? 
 Do you ever feel down/low mood? 
 Do you ever feel anxious/worried/stressed? 
 Has this changed recently or has it been stable? 
 Have you felt down or anxious at some point in the past? 
 
 Other difficulties 
 How is your sleep? 
 How is your appetite? 
 Do you find it hard to concentrate? 
 
 Self-harm/suicidality – risk assessment 
 
 Current functioning 
 What does your day look like at the moment? 








 Early memories – including experience of trauma/abuse/neglect/losses 
 What was it like for you growing up? 
 
 Relationships with parents, siblings, significant others 
 Who was around when you were growing up? 
 How did you get on with….? 
 
 Primary and Secondary School 
 Can you tell me a bit about school? 
 How did you find the academic work? 
 Did you have friends? 
 
 Educational/occupational history - timeline 
 When did you leave school? 
 What did you do afterwards? 
 
 Experiences of social exclusion, discrimination, stigma etc 
 Have you ever not been able to do something you wanted to do? 
 Do you feel you’ve been discriminated against? 
 
 Medical history 
 Have you ever had any major illnesses or health problems? 
 Have you ever spent any time in hospital? 
 




 Interpersonal relationships  
 Who is in your life at the moment? 
 Do you have a partner/children? 
 Tell me about your friends 
 Who do you talk to if you have a problem/need support? 
 
 Occupation 
 Do you work? What do you do? 
 Do you enjoy it? 
 What did you do in the past? 
 
 Accommodation/financial worries 
 Do you worry about money? 
 Are you happy with where you live and who you live with? 
 
 Hobbies/interests 
 What hobbies/interests do you have? 
 Is there anything you used to do that you don’t do anymore? 




 Other concerns 
 Is there anything else in your life at the moment that worries you or 
that you’d like to be different? 
 
 
Thank you very much for talking to me today. Is there anything else that we haven’t 
talked about that you feel is relevant? Do you have any questions you’d like to ask 
me? 
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Version 2 (15/01/2018) 
 
DIARY GUIDE  
Investigating drop attacks 
 
Please use these guidelines when making your written diaries. However, there is no right or 
wrong information to record and this is a guide only.  
Try to record your diary as soon after the drop attack as you can. Try to write after every 
drop attack you have. 
Try to give as detailed an account of what happened before the attack, during the attack and 
afterwards. You can use the following questions to help you to remember different aspects 
of the experience: 
Before 
• What had you been doing in the hours before the drop attack? 
• What had you been doing immediately beforehand? 
• Who were you with? Where were you? What was the environment like? 
• How were you feeling beforehand? Happy, sad, stressed, worried, excited etc. 
• How did your body feel? Any aches/pains? Shaking or unsteadiness? 
• What was going through your head? What was on your mind? 
During 
• Try to describe the drop attack. 
• What do you remember about it? 
• How did your body feel? 
• How did it feel? Were you frightened/embarrassed/calm? 
• Was there anything going through your head? 
• Were other people around? How did they react? 
After 
• What happened afterwards? 
• Did other people help you? What was that like? 
• How did you feel (e.g. happy, sad, calm, upset, scared, relieved, worried etc.) 
• What were you thinking about what had just happened? 
• What did you do next? Did you change your plans? 
• Did you need to take time to recover? 
 
If you have any questions about writing your diary, please contact me on Tel: 
xxxxxxxxxxx 






Appendix I: Funnel plots 
 
 












Funnel plot of studies in the repeated measures functional symptoms comparison 
 
 
Funnel plot of studies in the between-groups depression symptoms comparison 
 
 
Funnel plot of studies in the between-groups anxiety symptoms comparison 
 
 
Funnel plot of studies in the repeated measures depression symptoms comparison 
 
 
Funnel plot of studies in the repeated measures anxiety symptoms comparison 
 
